

# POSTER PRESENTATION GUIDELINES

## OVERVIEW

Poster sessions are designed to give presenters an opportunity to discuss informally their research with colleagues interested in their research. The purpose of the posters is to visually stimulate interest in the research, to present sufficient information for viewers to understand the methods, results, and significance of the research, and to promote conversations and networking among conference participants.

## POSTER SESSION

Posters will be displayed in Pavilion 4 of the Lisboa Congress Centre from August 25–27. Each day will have a separate poster session:

Friday, August 25, Poster Session A

Saturday, August 26, Poster Session B

Sunday, August 27, Poster Session C

### 1. Set Up

8:00AM-9:00AM. All posters must be up by 8:45AM.

### 2. Hours

Pavilions 4/5 will be open from:

8:00AM - 5:00PM .....Friday and Saturday

8:00AM - 2:00PM .....Sunday

All breaks and lunches, as well as exhibits, will be located in Pavilions 4/5.

### 3. Discussion Time

Presenters should be at their poster from 12:45-1:45PM.

EuroDURG, the European Drug Utilization Research Group, invites all poster presenters displaying their posters on Saturday, August 26, to participate in the EuroDURG poster walk. EuroDURG will offer presenters the opportunity to present their work and to discuss their results with an audience. Please be present at your poster site between 12:45pm and 1:45pm. When the poster walk chair and audience stops at your poster, please give a brief, 3-minute, presentation and to answer questions about your research

### 4. Poster Prizes

Each day a group of judges will select the three best posters of the session. The presenters will receive ribbons to display on the posters and an invitation to display their poster for the duration of the ICPE.

### 5. Take Down

All posters must be taken down by 6:30PM on Friday and Saturday; posters must be taken down by 2:30PM on Sunday.

**NOTE:** *ISPE and the Lisboa Congress Centre will not be responsible for any poster that is left up overnight or is lost or damaged.*

## NUMBERING SYSTEM

Each poster board will be numbered. The poster number is the first number listed for the abstract on the following pages. Presenters should attach their posters to the board number corresponding to the number assigned to their poster in the Final Program. **Please note** the number may differ from that shown in the preliminary program. The abstract number, for use in locating abstracts in the final program and the special issue of *Pharmacoepidemiology and Drug Safety*, is in brackets [ ] after the title of the abstract.

## POSTER SPECIFICATIONS

1. Posters must be designed to fit a space 1 meter WIDE by 2.5 meters HIGH. *Suggested poster dimensions: 0.93 meters WIDE (3 feet) by 1.63 meters HIGH (5 feet).* The board will be the only support device available. Business cards or small leaflet literature for distribution may be inserted in an envelope and affixed to the board. POSTER ORIENTATION: PORTRAIT.
2. Posters may be attached to the boards using 2-sided Velcro tape. All poster presenters are encouraged to bring their own roll of 2-side Velcro tape.

22nd

ICPE

— Pharmacoeconomics  
for Public Health

---

August 24-27, 2006

Lisboa Congress Centre Lisbon, Portugal



- 1 **Diagnostic Characteristics of CD4 Cell Count Response in Predicting Virologic Response in HIV-Infected Patients Initiating HAART in Botswana [I43]**  
Gregory Bisson, Robert Gross, Tendani Gaolathe, Ian Frank, Caitlin Rollins-Kantrowitz, Scarlett Bellamy, Rachel Weinstein, Diana Dickinson, Harvey Friedman, Howard Moffat, Brian Strom, Ndwapi Ndwapi. (United States)
- 2 **Incidence and Risk Factors for Weight Loss during Dual HIV/Hepatitis C Virus Therapy [I44]**  
V Lo Re III, J Kostman, R Gross, R Reddy, M Putt, I Frank, B Strom. (United States)
- 3 **Antibiotic Use in Italian Hospitals 2002-2004 [I45]**  
Maria Chiara Silvani, Elisabetta Poluzzi, Domenico Motola, Petar Strahinja, Antonio Vargiu, Laura Bersaglia, Alberto Vaccheri, Nicola Montanaro. (Italy)
- 4 **Use of Narrow-Spectrum Prophylactic Antibiotics Might Not be Considered as a Safe Approach in the Management of Women Hospitalized for Preterm Premature Rupture of Membranes (PPROM) [I46]**  
Carole Franceschini, Elise Maurel, Segolene Charra, Frederic Lirussi, Jean-Bernard Gouyon, Paul Sagot, Catherine Deneux-Tharoux, Marc Bardou. (France)
- 5 **Age and Sex Specific Antibacterial Prescribing in Norway [I47]**  
Irene Litleskare, Hege S Blix, Anders Engeland, Marit Ronning. (Norway)
- 6 **High Level, but Not Low Level HIV Breakthrough on Efavirenz-Based Regimens Associated with Poor Adherence [I48]**  
Robert Gross, Warren B Bilker, Jennifer Chapman, James C Coyne, Harvey M Friedman, Brian L Strom. (United States)
- 7 **Influence of the 3rd Generation Cephalosporins Utilization on the Occurrence of ESBL-Positive Klebsiella pneumoniae [I49]**  
Karel Urbanek, Milan Kolar, Yvona Loveckova, Lucie Santava. (Czech Republic)
- 8 **Comparative Study of Antimicrobials Utilization in Intensive Care Units in a Region of Belarus [I50]**  
Maxim N Mily, Mihail L Pivovar, Sergey A Golubev. (Belarus)
- 9 **Profile of the Adverse Reactions of Anti-Infective Notified to the National Center of Monitoring of Medicines – NCMM in the Year of 2005 [I51]**  
Leandro Alves Macedo da Silva, Alzeir Santana Santos, Murilo Freitas Dias, Elane Alves Faria. (Brazil)
- 10 **Prevalence, User Profiles and Health Correlates of Hormone Therapy among German Women before and after WHI Study [I52]**  
Yong Du, Hildtraud Knopf, Hans-Ulrich W Melchert, Christa Scheidt-Nave, Marianne Braemer-Hauth, Ellen Pabel. (Germany)
- 11 **Cyproterone Acetate + Ethinyloestradiol as a Treatment for Women with Acne, Hirsutism – What Is the Risk Profile? [I53]**  
Helen E Seaman, Julia Snowball, Corinne S de Vries. (United Kingdom)
- 12 **Health Outcomes in Women Taking Ethinylestradiol/Drospirenone and Other Oral Contraceptives [I54]**  
Jeanne Loughlin, John Seeger, P Mona Eng, C Robin Clifford, Jennifer Cutone, Alexander Walker. (United States)
- 13 **European Active Surveillance Study of Women Taking HRT (EURAS-HRT) [I55]**  
Anita Assmann, Juergen C Dinger, Heinemann AJ Heinemann. (Germany)
- 14 **Descriptive Study of Users of Depo-Medroxyprogesterone Acetate (DMPA) in the MHRA GPRD [I56]**  
D Sanchez Matienzo, L L Lanza, L J McQuay, L Gutierrez, A Arana, S Perez-Gutthann. (Spain)
- 15 **ThromboEmbolismHormoneStudy – A Molecular Epidemiological Nationwide Case-Control Study on Risk and Susceptibility Factors for Venous Thromboembolism in Women [I57]**  
Annica Bergendal, Helle Kieler, Ingemar Persson. (Sweden)
- 16 **The OSIAP Europe Project: Presentation of a European Pharmacoepidemiological Survey of the Misuse or Abuse of Marketed Drugs [I58]**  
Maryse Lapeyre-Mestre, Mireille Gony, Ulf Bergman, Alfonso Carvajal, Anita Conforti, Eibert R Heerdink, Diego Macias, Robert Vander Stichele. (France)
- 17 **Profile of the Adverse Reactions of Drugs That Act in the Nervous System Notified to the National Center of Monitoring of Medicines – NCMM in the Year of 2005 [I59]**  
Alzeir Santana Santos, Leandro Alves Macedo da Silva, Murilo Freitas Dias, Elane Alves Faria. (Brazil)
- 18 **Comparative Safety of Long-Acting Bronchodilators [I60]**  
Michele M Jara, Stephan F Lanes, Charles Wentworth III, Corey May, Steven Kesten. (United States)
- 19 **Morbidity and Mortality among Users of Tiotropium in Denmark [I61]**  
Cynthia de Luise, Stephan F Lanes, Lars Pedersen, Jacob Jacobsen, Henrik T Sorensen. (United States)
- 20 **Asthma Exacerbations and Costs in Children Receiving Leukotriene Receptor Antagonists Versus Other Asthma Controllers [I62]**  
Miriam C Sturkenboom, Gino Picelli, Antonio Scamarcia, Luigi Cantarutti, Vasilisa Sazonov Kocevar, Gea Bonetto, Carlo Giaquinto, Eugenio Baraldi. (Netherlands)
- 21 **Outcomes of Income-Based Deductibles and Prescription Co-Payments in Older Users of Inhaled Medications [I63]**  
Colin R Dormuth, Malcolm Maclure, Robert J Glynn, Peter Neumann, Alan M Brookhart, Sebastian Schneeweiss. (Canada)
- 22 **Use of Proton Pump Inhibitors and the Risk of Community Acquired Pneumonia [I64]**  
Sinem Ezgi Gulmez, Anette Holm, Henrik Frederiksen, Court Pedersen, Jesper Hallas. (Denmark)
- 23 **Herpes Zoster (HZ) Epidemiology and Associated Health Care Use in Olmsted County, MN [I65]**  
Patricia Saddier, Barbara Yawn, Peter Wollan, Marge Kurland, Lina Sy, James Pellissier, Robbin Itzler. (United States)
- 24 **Adverse Events Associated with Purified Chick Embryo Cell Culture Rabies Vaccine in the United States [I66]**  
Azra Dobardzic, Hector S Izurieta, John K Iskander, Sean Shadomy, Emily J Woo, Charles Rupperecht, Gulliermo Herrera, Miles Braun, Robert Ball. (United States)

- 25 Spontaneous Reports of Breakthrough Varicella in Individuals Vaccinated with VARI-VAX™ [Varicella Virus Vaccine Live (Oka/Merck)] [167]  
S Galea, A Sweet, R Sharrar, P Beninger. (United States)
- 26 Evaluating Adverse Events after Vaccination in the Medicare Population [168]  
Dale R Burwen, Lawrence La Voie, M Miles Braun, Peter Houck, Rebecca Hudson, Robert Ball. (United States)
- 27 Post-Licensure Safety Surveillance of Diphtheria, Tetanus Toxoids, Acellular Pertussis, Hepatitis B and Inactivated Poliovirus Vaccine Combined (DTaPHE) from the U.S. Vaccine Adverse Event Reporting System (VAERS) [169]  
Soju Chang, Karen Farizo, M Miles Braun, Robert Ball. (United States)
- 28 Incidence of Congenital Anomalies in the UK [170]  
Patrick DeLisle, Paula Long, Kenneth Hornbuckle, Simon Voss. (United Kingdom)
- 29 Bupropion in Pregnancy and the Prevalence of Congenital Malformations [171]  
J Alexander Cole, Kelly S Oh, Claire C Chiang, Sherry M Mentor, Jack G Modell, Barbara R Haight, Irene S Cosmatos, Alexander M Walker. (United States)
- 30 Use of Selective Serotonin Reuptake Inhibitors in Early Pregnancy and Risk of Cardiac Malformations [172]  
M K Bakker, W S Kerstjens-Frederikse, M D Van den Berg, L TW De Jong-Van den Berg, H EK De Walle. (Netherlands)
- 31 First Trimester Exposure to SSRIs and the Risk of Birth Defects [173]  
Carol Louik, Angela E Lin, Martha M Werler, Sonia Hernandez-Diaz, Allen A Mitchell. (United States)
- 32 Use of an Insurance Claims Database To Characterize Women Exposed to Bupropion Versus Other Antidepressants during Pregnancy [174]  
J Alexander Cole, Kelly S Oh, Claire C Chiang, Jack G Modell, Barbara R Haight, Irene S Cosmatos, Alexander M Walker. (United States)
- 33 Does Folic Acid Protect Against Heart Anomalies among Children with Down Syndrome? [175]  
Willemijn M Meijer, Martha M Werler, Carol Louik, Sonia Hernandez-Diaz, Allen A Mitchell. (Netherlands)
- 34 Gestational Exposure to Paroxetine and Cardiac Malformations in Infants: A Nested Case-Control Study [176]  
Anick Berard, Elodie Ramos, Driss Oraichi, Lucie Blais, Evelyne Rey. (Canada)
- 35 Maternal Use of Oral Contraceptives and Risk of Hypospadias – A Population-Based Case-Control Study [177]  
Pia Wogelius, Erzsébet Horváth-Puhó, Lars Pedersen, Mette Nørgaard, Andrew E Czeizel, Henrik Toft Sørensen. (Denmark)
- 36 GPRD as a Tool for Investigating Teratogenicity [178]  
Arlene M Gallagher, Tim J Williams, Tjeerd P van Staa. (United Kingdom)
- 37 Effective Use of Supplemental Data in a Pregnancy Exposure Registry [179]  
Hugh Tilson, Heather Watts, Deborah Covington. (United States)
- 38 Maternal Use of Erythromycin and Risk of Congenital Malformations: A Population-Based Cohort Study [180]  
Pia Wogelius, Mette Gislum, Mette Nørgaard, Lars Pedersen, Vera Ehrenstein, Henrik Toft Sørensen. (Denmark)
- 39 Surveillance of Asthma-Related Drugs during Pregnancy Using a Health Insurance Claims Database [181]  
J Alexander Cole, Michael Doherty, Linda M Nelsen, Kristine E Shields, Alexander M Walker. (United States)
- 40 Perception of Teratogenic and Foetotoxic Risk by Health Professionals: A Survey in Midi-Pyrenees Area [182]  
Juliette Pichereau, Atul Pathak, Isabelle Lacroix, Jean-Louis Montastruc, Maryse Lapeyre-Mestre, Christine Damase-Michel. (France)
- 41 Optimal Comparison Groups for New User Designs [183]  
Robert J Glynn, Soko Setoguchi, Til Sturmer, Daniel H Solomon, Sebastian Schneeweiss. (United States)
- 42 Monitoring for Drug Interactions in a Post-Marketing Surveillance Database Using Multi-Item Proportionate Reporting Rate Ratios [184]  
Vitali Pool, Brenda Crowe, Sebastian Sorsaburu, Mark E Bangs. (United States)
- 43 Methods To Pool Infrequent Adverse Event Data: Neutropenia in Rheumatoid Arthritis [185]  
Nawab Qizilbash, Emilio Leton, Michael Wiper, Paul Dolin. (United Kingdom)
- 44 An Approach to Quantifying Confounding by Indication Due to Missing Information [186]  
Linda E Levesque, Sophie Dell'Aniello, Amina Barhdadi, Samy Suissa. (Canada)
- 45 Methodological Implications of the Heterogeneity of NSAIDs Users [187]  
Abdelilah Abouelfath, Cecile Droz, Nicholas Moore, Fanny Depont, Michel Amouretti, Patrick Blin, Annie Fourrier, The CADEUS Study Team. (France)
- 46 Modeling Cumulative Dose and Duration of Drug Exposure Using Splines [188]  
Marie-Pierre Sylvestre, Michal Abrahamowicz, Robyn Tamblyn. (Canada)
- 47 Signal Detection Method Taking Seriousness into Account [189]  
Takashi Omori. (Japan)
- 48 Discriminating the Wheat from Chaff: Automated Methods for Separating Safety-Related Signals from Indication-Related Signals in Data Mining Spontaneous Reports [190]  
A M Grady, D E Vanderwall, M Yang, D M Fram, W A DuMouchel. (United States)
- 49 An Analysis of the Exclusion Criteria Used in Observational Pharmacoepidemiological Studies [191]  
Michael J Perrio, Patrick C Waller, Saad AW Shakir. (United Kingdom)
- 50 The Application of Multiple Imputation Techniques To Identify Missing Cause of Failure [192]  
Amir Abbas Tahami Monfared, Elham Rahme. (Canada)
- 51 Factor Analysis as a Tool To Study Metabolic Syndrome as a Predictor of Cardiovascular Disease [193]  
Juhaeri Juhaeri, Rhonda L Bohn. (United States)

- 52 **Defining Antibiotic Exposure at the Individual- and Group-Level for Studying Antibiotics as Risk Factors for Acquiring Resistant Nosocomial Infections [194]**  
Sibel Ascioğlu, Marc Lipsitch, Matthew H Samore. (United States)
- 53 **Underestimation of Variance Due To Using Simple Random Sampling Statistical Methods Applied to Data Obtained from a Cluster Sampling Design [195]**  
Jianmin Wang, Amanda Allshouse, William Irish. (United States)
- 54 **Use of Drug Safety Profiling for Assessment of Drug Combinations – A Forgotten Tool? [196]**  
Andrzej Czarniecki, Simon Voss. (United Kingdom)
- 55 **Instrumental Variables and Survival Outcomes: The Effect of Pancreas-Kidney Versus Kidney Transplantation on Mortality [197]**  
Edwin P Martens, Wiebe R Pestman, Anthonius de Boer, Svetlana V Belitser, Yves FC Smets, Rudi GJ Westendorp, Olaf H Klungel. (Netherlands)
- 56 **Meta-Analysis with Individual Patient Data of the Efficacy of Oral Naftidrofuryl Versus Placebo in Intermittent Claudication [198]**  
Tine De Backer, Robert H Vander Stichele, Luc Van Bortel, Philippe Lehert. (Belgium)
- 57 **Approaches to Reducing Confounding by Indication in a Study of Breast Cancer Prognosis in Relation to the Use of Antidepressants after Diagnosis [199]**  
Jessica Chubak, Denise M Boudreau, Diana SM Buist, Barbara McKnight, Mary Anne Rossing, Noel S Weiss. (United States)
- 58 **Methodologic Considerations in the Evaluation of Sub-Population Specific Therapeutic Effects [200]**  
Jay S Kaufman. (United States)
- 59 **Survival Analysis with Frailty in the Behavioural Toxicity of Mianserin and Fluoxetine [201]**  
Alexandre G Silva, Rita Figueirinha. (Portugal)
- 60 **Pseudo-Panel Data Framework: Evidence from the National Health Survey – Portugal [202]**  
Mónica Inês, Nicoletta Rosati. (Portugal)
- 61 **Patient-Reported Adverse Events Occurring under Asthma Therapy – A Community Pharmacy-Based Survey [203]**  
Laurent Laforest, Eric Van Ganse, Gilles Devouassoux, Brice Kitio, Jacques Massol, Gisele Bauguil, Genevieve Chamba. (France)
- 62 **Use of the National Hospital Discharge Survey To Understand the Occurrence of Critical Limb Ischemia and Its Outcome: Planning for Early Drug Development [204]**  
Joanna F Haas, Kathryn Starzyk, Rhonda L Bohn. (United States)
- 63 **The Use of Individual Risks Rather Than Population Averages in Cost-Effectiveness Modeling [205]**  
Tjeerd P van Staa, Piet Geusens, Annelies Boonen, Cyrus Cooper, Hubert GM Leufkens. (United Kingdom)
- 64 **A Cohort Study on Effectiveness and Safety of TNF-Blockers in Severe Rheumatoid Arthritis [206]**  
Marina Maggini, Roberto Raschetti, Giacoma C Sorrentino, Bruno Caffari, Clara Bianchi, Paolo Sfriso, Laura Sottosanti, Silvano Todesco. (Italy)
- 65 **Not All Patients Are Average: The Importance of Epidemiological Data in Pharmacoeconomic Modeling [207]**  
Tjeerd P van Staa, Annelies Boonen, Piet Geusens, Cyrus Cooper, Hubert GM Leufkens. (United Kingdom)
- 66 **The Effect of Iron Supplementation 2 Times Daily with or without Meals for 12 Weeks in Trimester 2 & 3 Pregnant Women with Iron Deficiency Anemia and Low Heme Diet [208]**  
Erna Kristin, Mohammad Hakim, Sri Kadersih Soejono, Lukman Hakim. (Indonesia)
- 67 **Abstract Withdrawn [209]**
- 68 **ADR-Related Hospitalisations: A Population-Based Cohort Study [210]**  
Cornelis S van der Hooff, Jeanne P Dieleman, Claire Simes, Albert-Jan Aarnoudse, Katia MC Verhamme, Bruno HCh Stricker, Miriam CJM Sturkenboom. (Netherlands)
- 69 **Evaluation of Rapidly Discontinued Medication Orders in a Computerized Physician Order Entry System (CPOE) [211]**  
Charles E Leonard, Ross Koppel, A Russell Localio, Abigail Cohen, Brian L Strom. (United States)
- 70 **Concomitant Use of Statins and CYP3A4 Inhibitor Drugs: Data from 380 000 Statin Users [212]**  
Eileen E Ming, Marcelo A Marotti, Sanjay K Gandhi, Pia S Pollack. (United States)
- 71 **Elderly Patients in Stockholm Are Commonly Prescribed Drugs That Require Precautions in Relation to Reduced Renal Function [213]**  
Ingegerd Odar-Cederlof, Susanne Sjoviker, Sten Ronge, Anders Hellden, Anders Soderstrom, Lennart Jacobsson, Lars L Gustafsson, Eva Andersen-Karlsson, Seher Korkmaz, Linus Fred, Ake Nilsson, Ulf Bergman. (Sweden)
- 72 **Effect of Computerized Physician Order Entry with Clinical Decision Support on Adverse Drug Events in the Long-Term Care Setting [214]**  
Jerry H Gurwitz, Terry Field, Paula Rochon, James Judge, Leslie Harrold, Monica Lee, Kathleen White, Jane Laprino, Janet Erramuspe-Mainard, Martin DeFlorio, Linda Gavendo, Chaim Bell, David Bates. (United States)
- 73 **Is Hospitalisation a Determinant for Discontinuity of Drug Use? [215]**  
Rutger Stuffken, Eibert R Heerdink, Fred HP de Koning, Patrick C Souverein, Antoine CG Egberts. (Netherlands)
- 74 **Rates of Serious Adverse Events in Patients on High Risk Medications [216]**  
Joshua P Metlay, Sean Hennessy, Russell Localio, Charles E Leonard, Jennifer Tjia, Abigail Cohen, Kevin Haynes, Wei Yang, Xiaoyan Han, Stephen E Kimmel, Harold I Feldman, Brian L Strom. (United States)
- 75 **Assessment of Preventability of Adverse Drug Effects Detected in an Emergency Department [217]**  
Marie-Laure Laroche, Séverine Boqueho, Yves Nouaille, Christine Vallejo, Louis Merle. (France)
- 76 **Oral Anticoagulation and Prevention of Bleeding [218]**  
Steinar Madsen, Bente Werner. (Norway)
- 77 **Adoption of Electronic Prescribing in U.S. Community-Based Medical Practices [219]**  
Michael A Fischer, Christine Vogeli, Margaret Stedman, Daniel Z Sands, Rainu Kaushal, Joel S Weissman. (United States)

- 78 **Is There a Ratio That Can be Used To Predict Harm from Minor Medication Errors?** [220]  
Katja Taxis, Steve Gallivan, Bryony Dean Franklin, Nick Barber. (Netherlands)
- 79 **A Systematic Review of the Nature of Preventable Adverse Drug Events in Ambulatory Care** [221]  
Linda Aa Thomsen, Birthe Sondergaard, Almut G Winterstein, Lotte S Haugbolle, Arne Melander. (Denmark)
- 80 **A Case-Control Study of the Risk of Cerebrovascular Adverse Events Following Treatment with Antipsychotics in an Elderly Demented Population** [222]  
Lesley H Wise, David Irvine, Jane N Moseley. (United Kingdom)
- 81 **The Yellow Card Scheme: Evaluation of Patient Reporting of Suspected Adverse Drug Reactions** [223]  
S Ekins-Daukes, D Irvine, L Wise, S Fiddes. (United Kingdom)
- 82 **Male Infertility and Drug Consumption: Result of a Case-Control Study** [224]  
Isabelle Lacroix, Benoit Marquier, Roger Mieusset, Alain Berrebi, Jean-Louis Montastruc, Maryse Lapeyre-Mestre, Christine Damase-Michel. (France)
- 83 **Evaluating Telithromycin-Related Hepatotoxicity; an Application of the Case-Control Design to Spontaneous Report Data** [225]  
David D Dore, Julia R DiBello, Kate L Lapane. (United States)
- 84 **An Evaluation of Computer-Aided Disproportionality Analysis for Post-Marketing Signal Detection** [226]  
Heidi Lehman, Jie Chen, A Lawrence Gould, Raymond Kassekert, Data Mining Committee. (United States)
- 85 **Incidence of Drug-Induced Agranulocytosis in Hospital: A Prospective Analysis from Laboratory Signals** [227]  
Neda Tavassoli, Haleh Bagheri, Eliane Duchayne, Maryse Lapeyre-Mestre, Pierre Sie, Jean-Louis Montastruc. (France)
- 86 **Reports of Acute Angle Closure Glaucoma-Related Adverse Events with SSRIs: Results of a Disproportionality Analysis** [228]  
Manfred Hauben, Lester Reich. (United States)
- 87 **Standardised MedDRA® Queries: Analysis of Their Signal Detection Capability** [229]  
Victoria Newbould, Nick Halsey, Panos Tsintis, Magnus Lerch, Patricia Mozzicato. (United Kingdom)
- 88 **Swedish Register-Based Monitoring of Drug Safety in Rheumatoid Arthritis** [230]  
C Michael Fored, Johan Asklung. (Sweden)
- 89 **Abstract Withdrawn** [231]
- 90 **Accelerated Reporting of Vaccine Adverse Events: A Novel Approach for Enhanced Pharmacovigilance** [232]  
Rachel J Summers, Aaron B Mendelsohn, Samuel Yonren. (United States)
- 91 **Prescription-Event Monitoring Study of Oxcarbazepine as Used in General Practice in England** [233]  
Beverley R Twaites, Lynda V Wilton, Saad AW Shakir. (United Kingdom)
- 92 **Low-Potency and Atypical Antipsychotics Were Associated with Pulmonary Embolism among Swedish Autopsy Cases** [234]  
Anna K Jonsson, Lars Brudin, Johan Ahlner, Karin Hedenmalm, Anders Eriksson, Staffan Hagg. (Sweden)
- 93 **Post-Marketing Hepatic Adverse Event Reporting in the EU, Japan and USA** [235]  
John J Pasquale, Linda C Koo, Piet AM Vervaeet. (United States)
- 94 **Relationship between Drug-Drug Interactions and Adverse Drug Effects: A Case-Control Study** [236]  
Marie-Laure Laroche, Dominique Plats, Jean-Pierre Charnes, Louis Merle. (France)
- 95 **Comparing Data Mining Algorithms in Pharmacovigilance: Points To Consider for Prospective Surveillance** [237]  
Manfred Hauben, David I Goldsmith, Sean Mahar, Vaishali Patadia. (United States)
- 96 **Spontaneously Reported Fatal Adverse Drug Reactions: A 10-Year Survey from Sweden** [238]  
Karin Wester, Anna K Jonsson, Olav Spigset, Staffan Hagg. (Sweden)
- 97 **The Pharmacoepidemiology of Carisoprodol Misuse and Abuse** [239]  
Jørgen G Bramness, Kari Furu, Anders Engeland, Svetlana Skurtveit. (Norway)
- 98 **Spontaneous Reports of Asthma-Related Adverse Events with Acetaminophen: Results of a Disproportionality Analysis** [240]  
Manfred Hauben, Lester Reich. (United States)
- 99 **A Statistical Approach To Duplicate Detection in Adverse Drug Reactions Monitoring** [241]  
G Niklas Norén, Andrew Bate, Roland Orre, I Ralph Edwards. (Sweden)
- 100 **The Relation between Hepatitis B and Demyelinating Diseases: A Data Mining Analysis of a Phantom Ship Association in VAERS** [242]  
Charles M Gerrits, Motonobu Sakaguchi, Manfred Hauben, Vaishali Patadia. (United States)
- 101 **Using Report Quality Indicators Increases Power for Safety Signal Detection** [243]  
Xionghu Yang, David Fram, William DuMouchel. (United States)
- 102 **Illusion of Objectivity and Recommendations for Reporting Data Mining Results** [244]  
Manfred Hauben, Lester Reich, Charles Gerrits. (United States)
- 103 **Drowsiness and Sedation: A Comparison between Levocetirizine and Desloratadine Using Post-Marketing Observational Data from Prescription-Event Monitoring (PEM) Studies** [245]  
Deborah Layton, Andrew Boshier, Lynda Wilton, Victoria Cornelius, Saad Shakir. (United Kingdom)
- 104 **Anaphylactoid Reactions to Dextran 40 and 70: Reports to the US Food and Drug Administration (FDA)** [246]  
Craig E Zinderman, Laurence Landow Landow, Robert P Wise. (United States)
- 105 **Adverse Drug Reaction Reporting by Dispensing Pharmacists in Norway – A Pilot Study** [247]  
Ane Gedde-Dahl, Pernille Harg, Hanne Stenberg-Nilsen, Marit Buajordet, Anne G Granas, Anne M Horn. (Norway)
- 106 **Intervention To Improve Adverse Drug Reaction Reporting: A Cluster-Randomized Trial among Portuguese Pharmacists** [248]  
Teresa Herdeiro, Adolfo Figueiras, Manuela Pinto, Inês Vaz, Jorge Polónia. (Portugal)

- 107 Using Semantic Distance for Clustering ADR Case Reports with the WHO-ART Classification [249]  
Cédric Bousquet, Jimison Iavindrasana, Marie-Christine Jaulent. (France)
- 108 Applying Quantitative Methods for Detecting Drug Safety Signals in Pharmacovigilance National Database [250]  
Gloria Shalviri, Kazem Mohammad, Reza Majdzadeh, Kheirollah Gholami. (Islamic Republic of Iran)
- 109 Creation of a Pharmacovigilance Control Project in a Private Health Service [251]  
Diego A Arboleda, Fernando Guerrero, Martha Duarte, Eduardo Low, Gilma Diaz. (Colombia)
- 110 Signal Detection in the Evaluation of Bisphosphonate-Associated Osteonecrosis of the Jaw [252]  
Athanasios I Zavras, Gregg S Wilkinson. (United States)
- 111 Factors That Could Affect Adverse Drug Reaction Reporting by Community Pharmacists in Southern Portugal [253]  
L C Pinheiro, M Caneira, A P Martins, J Cabrita, J A Morais. (Portugal)
- 112 Mapping of the WHO-ART Terminology on Snomed CT To Improve Grouping of Related Adverse Drug Reactions [254]  
Iulian Alecu, Cédric Bousquet, Marie-Christine Jaulent. (France)
- 113 Abstract Withdrawn [255]
- 114 A Preliminary Comparison of the FDA-AERS Database and WHO Adverse Events Database for Purpose of Data Mining [256]  
Charles M Gerrits, Manfred Hauben, Vaishali Patadia. (United States)
- 115 A Pilot To Assess the Potential of Clinical Trials Data To Predict Postmarketing Signals of ADRs [257]  
Karen Wilcock, Bharat T Thakrar, Alan Nevitt. (Switzerland)
- 116 Comparison of the Quality of Spontaneous Adverse Drug Reaction Reports Received from Consumers Versus Healthcare Professionals in 2003 [258]  
Isaac W Hammond, Donna Rich, Lisa Laksh, Trevor G Gibbs. (United States)
- 117 Impact of Patient Outreach Programs on Consumer Reports of Adverse Events [259]  
Virgil Dias, Haiying Liu, Daniel Furst, Ed Keystone, Hal Paulus, James Louie, Sean Zhao, Atsuko Shibata. (United States)
- 118 Knowledge Acquisition for Formal Definitions of WHO-ART Terms [260]  
Cédric Bousquet, Jimison Iavindrasana, Marie-Christine Jaulent. (France)
- 119 Reports of Hyperkalemia after Publication of Rales – A Pharmacovigilance Study [261]  
Manfred Hauben, Lester Reich, Charles Gerrits. (United States)
- 120 Influence of Underreporting on Statistical Measures in Signal Detection [262]  
Eugene P van Puijenbroek, Mark CH de Groot, Kees van Grootheest. (Netherlands)
- 121 Assessment of Adverse Drug Reactions Reports Related to Pediatric Patients Sent to Pharmacovigilance Unit, Brazil [263]  
Milena O Bittencourt, Murilo F Dias, Leandro AM Silva, Jose Romerio R Melo, Patricia M Figueiredo, Alessandra A Costa. (Brazil)
- 122 Reporting of Adverse Drug Reactions to Complimentary and Alternative Medicines – Experiences and Results from an Indian Tertiary Care Hospital [264]  
Jimmy Jose, Padma GM Rao. (India)
- 123 Pattern of Adverse Drug Reactions Notified by Spontaneous Reporting in an Indian Tertiary Care Teaching Hospital [265]  
Jimmy Jose, Padma GM Rao. (India)
- 124 Cardiovascular Safety of Tadalafil in a Cohort of Users in England [266]  
Lorna Hazell, Scott Harris, Andrew Boshier, Wilton V Lynda, Shakir AW Saad. (United Kingdom)
- 125 Spontaneous Reports of Adverse Drug Reactions: A Retrospective Analysis Using the Portuguese Southern Regional Pharmacovigilance Unit Database [267]  
L C Pinheiro, M Caneira, A P Martins, J Cabrita, J A Morais. (Portugal)
- 126 Potential Use of Data Mining Algorithms for the Detection of “Surprise” Adverse Drug Reactions [268]  
Manfred Hauben, Lester Reich, Sebastian Horn. (United States)
- 127 Alpha-1 Proteinase Inhibitor (Human) Product Postmarketing Safety Surveillance [269]  
Tina Khoie, Kathryn A O’Connell, Ross L Pierce, Andrew Shrake, Craig E Zinderman, Robert P Wise. (United States)
- 128 Postmarket Adverse Event Reporting Rates: How Well Do They Approximate Incidence Estimates [270]  
Isaac W Hammond. (United States)
- 129 Adverse Effects of Medications in Portugal: A Preliminary Analysis of Hospital Discharge Data (1993 – 2003) [271]  
Pedro Marques-Vidal, Sara Marques-Vidal, Carlos Matias Dias. (Portugal)
- 130 Pharmacovigilance and Pharmacoepidemiology of Gastric Acid Suppressants and Risk of *C. difficile* Colitis: Scientific Developments at the Interface of Clinical Medicine and Public Health [272]  
Lester Reich, Manfred Hauben. (United States)
- 131 Database Size and the Power To Detect Safety Signals in Post Market Safety Surveillance [273]  
Isaac W Hammond, Harry A Seifert, Donna Rich. (United States)
- 132 Risk of Selected Outcomes among the Solid Organ Transplant Patients: A Systematic Literature Review [274]  
Lee L Lanza, Lili Wang, William D Irish, Teresa Simon. (United States)
- 133 A Data Mining Analysis in Two Spontaneous Reporting System Databases Using Placebo-Associated Adverse Events as “True Negatives” [275]  
Manfred Hauben, Damien Hirsch, Lester Reich. (United States)
- 134 Secondary Use of Primary Data: Potential of Use of Patient Safety and Risk Management System for Drug Safety Related Post Market Surveillance [276]  
Ali H Rashidee, Sanjaya Kumar, Jack Chen. (United States)
- 135 Paracetamol Adverse Reactions Notified to the Northern Portugal Pharmacovigilance Unit by an Immunoallergology Department [277]  
Inês R Vaz, Manuela Pinto, Jorge Polónia, Altamiro Costa-Pereira, Josefina Rodrigues. (Portugal)

- 136 **The Analysis of Potential Drug-Drug Interactions with Clinical Significance 'I' in Patients with Hypertension [278]**  
Nen-Chung Chang, Mei-Shu Lin, Yea-huei Kao Yang, Yen-Hui Chen. (Taiwan)
- 137 **Risk-Based Approach for Reviewing Adverse Event Data To Detect Potential Product Quality Defects [279]**  
Thomas C Aquilina, Aaron B Mendelsohn, Samuel Yonren. (United States)
- 138 **Use of Data Mining as an Adjunct to Prospective Pharmacovigilance of "Mature" or "Old" Products [280]**  
Manfred Hauben, Lester Reich. (United States)
- 139 **International Active Surveillance Study of Women Taking Oral Contraceptives (INAS-OC) [281]**  
Juergen C Dinger, Anita Assmann, Lothar AJ Heinemann. (Germany)
- 140 **Does Low Dose Warfarin Have a Low Recurrence of the Thrombotic Event in Taiwanese Population [282]**  
Mei-Shu Lin, Nen-Chung Chang, Yea-huei Kao Yang, Yen-Hui Chen. (Taiwan)
- 141 **Drug Allergies Notified by an Immunoallergology Department to Northern Portugal Pharmacovigilance Unit [283]**  
Manuela Pinto, Inês Vaz, Altamiro Costa-Pereira, Jorge Polónia, Josefina Rodrigues. (Portugal)
- 142 **Evaluation of Follow up Contacts with Health Professionals Reporting Suspected Adverse Drug Reactions in Central Portugal [284]**  
Ana F Macedo, Francisco B Marques, Carlos F Ribeiro. (Portugal)
- 143 **Post-Marketing Safety Profile of Ezetimibe in Black Patients [285]**  
Heidi Lehman, David Andrulonis, Ingrid Adamsons. (United States)
- 144 **The WHO Drug Dictionaries – Concepts, Design and Uses [286]**  
Marcela Zemkova, Jitka Pokladnikova, Daniel von Sydow, Ronald HB Meyboom, Ralph I Edwards. (Czech Republic)
- 145 **Sclerosing Peritonitis as a Long-Latency Adverse Reaction to Practolol [287]**  
R D Mann. (United Kingdom)
- 146 **Interaction between Genetic Polymorphisms in the Renin-Angiotensin-System and the Risk of Diabetes Associated with the Use of ACE Inhibitors [288]**  
Özlem Bozkurt, Monique WM Verschuren, Anthonius de Boer, Diederick E Grobbee, Mirjam I Geerlings, Rob E Heerdink, Bruno HCh Stricker, Olaf H Klungel. (Netherlands)
- 147 **The Multidrug Resistance I Gene C3435T Polymorphism Is Associated with Increased Digoxin Blood Concentration [289]**  
Albert-Jan LHJ Aarnoudse, Jeanne P Dieleman, Loes E Visser, Ron HN van Schaik, Andre G Uitterlinden, Bruno HCh Stricker. (Netherlands)
- 148 **VKORCI and CYP2C9 Genotypes and Acenocoumarol Anticoagulation Status: Interaction between Both Genotypes Affects Overanticoagulation [290]**  
Tom Schalekamp, Bjorn Brassé, Janine FM Roijers, Youssef Chahid, Johanna HH van Geest-Daalderop, Hanneke de Vries-Goldschmeding, Eduard M van Wijk, Antoine CG Egberts, Anthonius de Boer. (Netherlands)
- 149 **Enhancing Signal Detection for Pharmacovigilance Using Pharmacogenomics [291]**  
Pendar Farahani, Mitchell Levine. (Canada)
- 150 **The Association between 5-HT2c Polymorphisms and the Metabolic Syndrome in Patients Using Antipsychotics [292]**  
Hans Mulder, Hans Scheffer, Annemarie Van der Aart-Van der Beek, Johan Arends, Frederik W Wilmink, Antoine CG Egberts. (Netherlands)
- 151 **Challenges in Obtaining Ethical Approval for a Pilot Study To Obtain Biosamples in a UK Medical Records Database [293]**  
Kevin Haynes, Mary Thompson, Hassy Dattani, Alison Bourke, Sean Hennessy. (United States)
- 152 **No Change in Risk with Time of Ischaemic Cardiovascular Events from Selective Cyclooxygenase-2 Inhibitors [294]**  
Marianne Cunnington, David Webb, Nawab Qizilbash, David Blum, Adrian Mander, Michelle Funk, John Weil. (United Kingdom)
- 153 **Patients Willingness To Accept Risk-Benefit Tradeoffs in Treating Crohn's Disease [295]**  
F Reed Johnson, Semra Özdemir, Elizabeth B Andrews. (United States)
- 154 **Characteristics of Nefazodone Patients Receiving Baseline Liver Function Testing [296]**  
Elaine H Morrato, Robert J Valuck, Manning Feinleib. (United States)
- 155 **Changes in Liver Function Testing Following the Nefazodone Boxed Warning [297]**  
Elaine H Morrato, Robert J Valuck, Manning Feinleib. (United States)
- 156 **Using an Australian Linked Health Dataset To Assist Medical Practitioners Manage Therapeutic Risk: The Veterans' MATES Project [298]**  
Andrew L Gilbert, Elizabeth Roughead, Nicole Pratt, Robert Peck. (Australia)
- 157 **The Impact of Obesity on the Contraceptive Reliability of Oral Contraceptives [299]**  
Juergen C Dinger, Anita Assmann, Lothar AJ Heinemann. (Germany)
- 158 **Use of Emergency Contraception in Belgian Women [300]**  
Johan De Haes, Marc DeFalleur, Herman Beyers, André De Swaef. (Belgium)
- 159 **The Impact of Awareness on Enrollment in Pregnancy Exposure Registries [301]**  
Deborah Covington, Susan Roberts, Peggy Doi. (United States)
- 160 **Birth Weight, Oral Contraceptive Use, and Reproductive Period as Independent Factors Associated with Estrogen-Related Diseases at Middle Age: Japan Nurses' Health Study [302]**  
Kota Katanoda, Toshiharu Fujita, Takeshi Aso, Shosuke Suzuki, Hideki Mizunuma, Tomoko Kodama, Kunihiko Hayashi, The JNHS Group. (Japan)
- 161 **Drug Use in Pregnancy [303]**  
Marcel Leppée, Josip Culig, Marina Polic-Vizintin, Matijana Grgic. (Croatia)
- 162 **Drug Prescription Patterns before, during and after Pregnancy for Chronic, Occasional and Pregnancy-Related Drugs in the Netherlands [304]**  
Marian K Bakker, Janneke Jentink, Fokaline Yroom, Paul B Van Den Berg, Hermien EK De Walle, Lolkje TW De Jong-Van Den Berg. (Netherlands)

# Submit your papers to *Pharmacoepidemiology and Drug Safety* online

Saving you time and money, the online manuscript submission, tracking and peer-review service is the new way to submit your papers.

- No need for 3 copies and expensive photos – simply upload text and images
- No time waiting for the post – all correspondence is via e-mail
- Check the status of your manuscript at any time and from anywhere in the world
- View and respond to reviewers' comments and submit revisions instantly
- PDF proofs of accepted papers are sent by e-mail for faster processing

For further information, visit the 'For Authors' section on the journal homepage:  
**[www.interscience.wiley.com/journal/pds](http://www.interscience.wiley.com/journal/pds)**



Would you like to contribute to the success  
of *Pharmacoepidemiology and Drug Safety*?

Why not become a reviewer?

In response to the increasing number of submissions to PDS, we wish to expand our panel of reviewers. By making a substantial contribution to the development of the subject, reviewers are key to the progressive improvement of our journal. If you are interested in reviewing for PDS and have appropriate expertise, we would like to hear from you.

For further details please contact  
Professor Ron Mann, Editor-in-Chief ([ronmann@professormann.com](mailto:ronmann@professormann.com)) and  
Professor Brian Strom, Editor for the Americas ([bstrom@cceb.med.upenn.edu](mailto:bstrom@cceb.med.upenn.edu))

 WILEY  
**InterScience®**  
DISCOVER SOMETHING GREAT

- 163 Characteristics of French Women Presenting with Urinary Incontinence, Baseline Results from the PURE Study (Prospective Urinary Incontinence Research) [305]**  
Emmanuel Chartier-Kastler, Stephanie Tcherny-Lessenot, Sandra Avoinet, Brigitte Bosio-Le Goux. (France)
- 164 Migraine Incidence, Comorbidities and Health Resource Utilization in the United Kingdom [306]**  
Claudia Becker, Gunnar Brobert, Per Almqvist, Saga Johansson, Susan S Jick, Christoph R Meier. (Switzerland)
- 165 Angiotensinogen M235T Polymorphism and the Risk of Myocardial Infarction and Stroke among Hypertensive Patients on ACE-Inhibitors or beta-Blockers [307]**  
Hedi Schelleman, Olaf H Klungel, Jacqueline CM Witteman, Monique MB Breteler, Jan HJ Danser, Albert Hofman, Cornelia M van Duijn, Anthonius de Boer, Bruno HCh Stricker. (Netherlands)
- 166 Identifying Nonresponders to Asthma Therapy Using Leukocyte Parameters [308]**  
Karin J Velthove, Madelon Bracke, René C Schweizer, Maarten J ten Berg, Hubert GM Leufkens, Wouter W van Solinge. (Netherlands)
- 167 Is Use of Asthma Medication in Preschool Children Consistent with the Clinical Wheezing Phenotype? [309]**  
Mira G Zuidgeest, Madelon Bracke, Henriette A Smit, Bert Brunekreef, Hubert G Leufkens. (Netherlands)
- 168 Drug Utilisation Study of the Newer Antiepileptic Drugs in Children – Preliminary Results Using the General Practice Research Database (GPRD) [310]**  
Ruth Ackers, Macey Murray, Frank Besag, Ian Wong. (United Kingdom)
- 169 Antiepileptic and Psycholeptic Drugs Used in ADHD (Attention Deficit / Hyperactivity Disorder) in Addition to Methylphenidate [311]**  
Edda Wuerdemann, Katrin Janhsen, Gerd Glaeske. (Germany)
- 170 Incidence, Prevalence, and Demographic Differences in Central Nervous System Stimulant (CNSS) Use in Children and Adolescents with Attention Deficit Hyperactivity Disorder (ADHD): A Study of Florida Medicaid Beneficiaries 1994-2004 [312]**  
Tobias F Gerhard, Almut G Winterstein, Jonathan J Shuster. (United States)
- 171 The Use of Anti-Asthmatic Medications among Children in Salvador, Brazil [313]**  
Djanilson B Santos, Mauricio L Barreto, Helena Lutescia L Coelho. (Brazil)
- 172 A Time-Trend Analysis of All Clinical Activity, Amoxicillin/Co-Amoxiclav Prescribing, Acute Otitis Media and Acute Mastoiditis in Paediatrics in General Practice [314]**  
Paula L Thompson, Ruth Gilbert, Paul Long, Macey L Murray, Mike Sharland, Ian CK Wong. (United Kingdom)
- 173 Drug Utilization in Hospitalized Children in Fortaleza, Brazil [315]**  
Djanilson B Santos, Ana Lucia F Veneranda, Helena Lutescia L Coelho. (Brazil)
- 174 Lack of Medicines with Proper Formulation for Use in Children and Its Practical Repercussions in a Reference Pediatric Public Hospital in Fortaleza, Brazil [316]**  
Helena Lutescia L Coelho, Patricia Q da Costa, Janete Elisa S de Lima. (Brazil)
- 175 Pediatric Medication with Homeopathic and Herbal Drugs in the Survey for Children and Adolescents in Germany – The Heritage of Samuel Hahnemann [317]**  
Hans-Ulrich W Melchert, Knopf Hildtraud, Yong Du, Marianne Braemer-Hauth, Ellen Pabel. (Germany)
- 176 Study of Prescription Practice of Antipyretics for Pediatric Patients in Ambulatory Care in Bulgaria [318]**  
Ilko N Getov, Nikolay Kolev, Maria Nedialkova, Krassimira B Ilieva. (Bulgaria)
- 177 Appropriate Use of Chemotherapy for Cancer in Day-Hospital Settings in Italy [319]**  
Ambrogio Bottoni, Andrea Lanza, Cristina Meneghin, Giovanna Brusco, Giovanbattista Ippoliti. (Italy)

◀ **END SESSION A**

- 1 **Attention Deficit/Hyperactivity Disorder: A Preliminary Study in the Nelson Mandela Metropole [320]**  
Sanmari Snyman, Ilse Truter, Marosé Ferreira. (South Africa)
- 2 **Abstract Withdrawn [321]**
- 3 **Off-Label Prescriptions of Psychotropics Drugs in Subjects Hospitalised in Psychiatry: Frequency and Characteristics [322]**  
Claire Ricard, Hélène Verdoux, Karin Martin. (France, Metropolitan)
- 4 **Consumption of Statins in Valencian Community (Spain): 2000-2004 [323]**  
Amparo Zapater, Leonor Dominguez, Rocio Broseta, Fernando Fernandez-Llimos. (Spain)
- 5 **Consumption of Bisphosphonates in Valencian Community (Spain): 2000-2004 [324]**  
Fernando Fernandez-Llimos, Laura Monzon, Rocio Broseta, Amalia Ubeda. (Spain)
- 6 **Information Lost on Aggregating Consumption Data: Calcitonin in Valencian Community, Spain (2000-2004) [325]**  
Fernando Fernandez-Llimos, Laura Monzon, Marta Colomer, Rocio Broseta, Amalia Ubeda. (Spain)
- 7 **Antihyperglycemic Prescribing Trends for Patients with Type 2 Diabetes in Italy: A Descriptive Study in Primary Care [326]**  
Giampiero Mazzaglia, Nicole R Yurgin, Kristina Secnik, Gerardo Medea, Claudio Cricelli. (Italy)
- 8 **Consumption of Proton Pump Inhibitors in Valencian Community (Spain): 2000-2004 [327]**  
Carmen Velilla, Arturo Torregrosa, Rocio Broseta, Fernando Fernandez-Llimos. (Spain)
- 9 **Descriptive Study and Pharmacotherapeutic Advisory Intervention at a Medicine Clinic of a Large Hospital in Stockholm [328]**  
Buster Mannheimer, Johanna Ulfvarson, Monica Bergqvist, Christer von Bahr. (Sweden)
- 10 **Nurses' Attitudes to Medication Care in Nursing Homes: Results of the PHEBE Project [329]**  
Monique M Elseviers, Tom Defloor, Robert H Vander Stichele. (Belgium)
- 11 **Therapeutic Risk Management in Elderly with Reduced Renal Function [330]**  
SO Martins, MA Soares, SA Morais, B Rodrigues, J Cabrita. (Portugal)
- 12 **Polypharmacy in a Danish County [331]**  
K Schaefer, L O Henriksen, H Maerkedahl. (Denmark)
- 13 **The Effect of Quality Incentives in General Practice: Observations on Prescribing Patterns Using the Defined Daily Dose Method [332]**  
Sean P MacBride-Stewart, Tom Walley. (United Kingdom)
- 14 **Prevalence of Drug Treatment in Subjects with Alzheimer's Disease in France [333]**  
Antoine Pariente, Catherine Helmer, Nicholas Moore, Annie Fourrier, Jean-Francois Dartigues. (France)
- 15 **Prevalence of Drug Treatment in Subjects with Alzheimer's Disease in Europe [334]**  
Antoine Pariente, Catherine Helmer, Annie Fourrier, Nicholas Moore, Jean-Francois Dartigues. (France)
- 16 **Drug Utilization Review: Combination Therapy in Asthma [335]**  
Marie-Claude Breton, Jacques Le Lorier, Amelie Forget, Lucie Blais. (Canada)
- 17 **Risk of Lower Respiratory Tract Infection among Users of Inhaled Corticosteroids [336]**  
Marc Dorais, Jacques LeLorier. (Canada)
- 18 **Impact of the Socio-Economic Status on the Probability To Receive TZDs among Patient Who Meet the Criteria Reimbursement [337]**  
Marc Dorais, Jacques LeLorier. (Canada)
- 19 **Non-Steroidal Anti-Inflammatory Drug Prescription in Relation to the Prescribing of Gastroprotective Drugs in Australia [338]**  
Nadia Barozzi, Susan Tett. (Australia)
- 20 **Renal Risk Drugs Are Widely Used in Hospitalised Patients with Impaired Renal Function [339]**  
Hege S Blix, Kirsten K Viktil, Tron A Moger, Aasmund Reikvam. (Norway)
- 21 **Exploring the Dynamics of Disease Modifying Antirheumatic Drugs Utilization in Portugal [340]**  
Marta Soares, Valeska Andreozzi, Jorge Félix, Jaime C Branco, CURAR Study Group. (Portugal)
- 22 **Early Identification of Long Term Poor Compliance in Ambulatory Patients Using a Multivariate Risk Score Model [341]**  
Harm CJ Geers, Cornelis J de Blaey, Antoine CG Egberts, Eibert R Heerdink. (Netherlands)
- 23 **The Ever Increasing Use of Proton Pump Inhibitors in Norway [342]**  
Christian Berg, Kari Furu. (Norway)
- 24 **Adherence to Statin Therapy and Attainment of Guidelines - LDL-Cholesterol Therapeutic Objectives [343]**  
Brice Kitio, Laurent Laforest, Jacques Massol, Eric Van Ganse. (France)
- 25 **Characterization of US Adult Users of Antihypertensive Medications [344]**  
C Varas-Lorenzo, L McQuay, S Eaton, I Saez-Lloret, M Melero-Montes, D Miller, S Perez-Gutthann. (Spain)
- 26 **Defining Polypharmacy as the Use of Five or More Drugs Is of Limited Value in the Assessment of Drug-Related Problems [345]**  
Kirsten K Viktil, Hege S Blix, Tron Moger, Aasmund Reikvam. (Norway)
- 27 **How Many and Who Are Receiving Medication for Treatment of Diabetes Mellitus in Norway? [346]**  
Hanne Strom, Anders Engeland, Elisabeth Eriksen, Solveig Sakshaug, Marit Ronning. (Norway)
- 28 **Predictors of Appropriate Use of Anti-Asthma Drugs among Individuals Aged 12 to 45 Years [347]**  
Marie-Sophie Jobin, Jocelyne Moisan, Yves Bolduc, Eileen Dorval, Madone Turcotte, Jean-Pierre Gregoire. (Canada)
- 29 **Prescription Patterns of Major Antidepressant Drugs in Adults Diagnosed with Depression: A GPRD-Based Study [348]**  
Sebastien Bineau, Delphine Saragoussi, Nicolas Despiegel, Mondher Toumi, Patrice Verpillat. (France)
- 30 **Indications for Antidepressant Drug Prescribing in General Practice in the Netherlands [349]**  
Helga Gardarsdottir, Eibert R Heerdink, Liset van Dijk, Antoine CG Egberts. (Netherlands)
- 31 **SSRI Prescribing Patterns in the UK: 2000 - 2005 [350]**  
David Irvine, Lesley Wise. (United Kingdom)

- 32 Does Screening Lead to Medicalisation? [351]  
Jarir Atthobari, Ron T Gansevoort, Sipke T Visser, Paul E de Jong, Lolkje TW de Jong-van den Berg. (Netherlands)
- 33 Non-Steroidal Anti-Inflammatory Drug (NSAID) Use in Early Pregnancy; Is There a Problem? [352]  
Fokaline Vroom, Paul B van den Berg, Jacobus RBJ Brouwers, Lolkje TW de Jong-van den Berg. (Netherlands)
- 34 The Use of Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Pregnancy; When Evidence Is Scarce [353]  
Fokaline Vroom, Eric N van Roon, Paul B van den Berg, Jacobus RBJ Brouwers, Lolkje TW de Jong-van den Berg. (Netherlands)
- 35 The Impact of the Withdrawal of Rofecoxib on the Use of Other Analgesics and Proton Pump Inhibitors – A Time Series Analysis in Portugal [354]  
Joelle M Hoebert, Pieter Stolk, Svetlana V Belitser, Hubert GM Leufkens, Ana P Martins. (Netherlands)
- 36 Utilization of Granulocyte Colony Stimulating Factors in Chemotherapy Induced Neutropenia in Patients with Breast or Lung Cancer: Portugal [355]  
J Félix, J M Ferreira, P Borrego, F Duarte-Ramos, V Andreozzi, Urano Study Group. (Portugal)
- 37 Drug Utilization Study of Cough Medications in Coro, Venezuela [356]  
Lida E Zavala, Rafael Colman, Mariolga Bravo. (Venezuela)
- 38 Drug Utilization Survey by Mail or Home Interview: Effects on Response in Brazil [357]  
Andreia Ribeiro, Francisco Acurcio, Cibele Cesar, Carlos Klein, Suely Rozenfeld. (Brazil)
- 39 Influence of Time on Adherence to Statins [358]  
Brice Kitio, Laurent Laforest, Jacques Massol, Eric Van Ganse. (France)
- 40 Temporal and Personal Variability in Adherence to Statins [359]  
Brice Kitio, Laurent Laforest, Jacques Massol, Eric Van Ganse. (France)
- 41 Primary Care Physicians' Clinical Interests Do Not Affect Their Adoption of New Drugs: A Pharmacoepidemiologic Study [360]  
Torben Dybdahl, Jens Søndergaard, Jakob Kragstrup, Ivar S Kristiansen, Morten Andersen. (Denmark)
- 42 Comparative Utilization Study on Antibacterial Agents in Hospital Settings in Japan [361]  
Maya Takemura, Naoko Yoshida, Isao Adachi, Kiichiro Tsutani, Junichi Kawakami. (Japan)
- 43 Utilization Study on Japanese Traditional Medicines in an Academic Hospital in Japan [362]  
Naoko Yoshida, Maya Takemura, Hiromi Abe, Minami Kojima, Isao Adachi, Kiichiro Tsutani, Junichi Kawakami. (Japan)
- 44 Oral Hypoglycaemic Agents: Prescribing Patterns and Accordance with Some Items from IDF Guideline in Portugal [363]  
Filipa Duarte-Ramos, José Cabrita. (Portugal)
- 45 Contact Allergy to Topical Drugs: Prevalence in a Clinical Setting and Estimation of Frequency at the Population Level [364]  
Cristiane A Menezes de Pádua, Wolfgang Uter, Axel Schnuch. (Germany)
- 46 Indapamide to Other Thiazide-Type Diuretics Ratio in Portugal [365]  
Sofia Crisostomo, Zilda Mendes. (Portugal)
- 47 Use of Desmopressin in Elderly Patients in Denmark 2000-2004 [366]  
Torbjörn Callréus, Jens Søndergaard, Morten Andersen. (Denmark)
- 48 Quantifying Antibiotic Use, to What Detail? [367]  
Peter Mol, Roy Stewart, Betty Meyboom, Flora Haaijer-Ruskamp. (Netherlands)
- 49 Development and Impact of PROFIL, a Training and Communication Network Program for Community Pharmacists, on the Clinical Follow-Up of Moderate to Severe Chronic Renal Insufficiency Patients: A Cluster Randomized Controlled Trial [368]  
M Normandeau, D Lamarre, A Lord, MC Laliberté, D Berbiche, I Cantin, L Corneille, L Prud'homme, L Lalonde. (Canada)
- 50 Predictors of Polypharmacy: A Cross-Sectional Pilot Study in the Saudi Ministry of Health Hospital Outpatient Clinics [369]  
Mohamed A Alkelya, David H Kreling. (United States)
- 51 Impact of Once-Weekly Bisphosphonates on Persistence Rate and Adherence Level with Antiresorptive Therapies Used in Primary Prevention of Osteoporosis [370]  
Julie Blouin, Alice Dragomir, Louis-Georges Ste-Marie, Julio Cesar Fernandes, Sylvie Perreault. (Canada)
- 52 Utilization Pattern of Antihypertensives among Korean Elderly Outpatients with Essential Hypertension in Primary Care [371]  
Sun-Young Jung, Nam-Kyong Choi, Hwa-Jung Kim, Seokyoung Hahn, Byung-Joo Park. (Korea)
- 53 Antibiotics in Ambulatory Care – Prescription Habits in Four Major European Countries [372]  
Helena Koblihova, Matus Ferech, Samuel Coenen, Peter Stephens, Jiri Vlcek, Herman Goossens. (Belgium)
- 54 The Risk of Osteoporotic Fractures in Clinical Practice Is Reduced with Persistent Bisphosphonate Use [373]  
Christel HA van den Boogaard, Nancy S Breekveldt-Post, Wim G Goettsch, Hans Middelhoven, Niall O Lynch, Ron MC Herings. (Netherlands)
- 55 Medication Utilization in Elderly Medicare Beneficiaries with Parkinson's Disease [374]  
Denise L Orwig, Jian Ye, Mona Baumgarten, Lisa M Shulman. (United States)
- 56 Trends and Predictors of Antihypertensive Drug Use during Pregnancy: A Population-Based Study [375]  
Jules K Koffi, Oraichi Driss, Evelyne Rey, Lucie Blais, Anick Berard. (Canada)
- 57 Diffusion of Aromatase Inhibitors for Breast Cancer [376]  
Erin J Aiello, Ann M Geiger, Roy Pardee, Diana SM Buist, Gene Hart, Sarah M Greene, Lois Lamerato, Terry Field, Ed Wagner. (United States)
- 58 Potentially Inappropriate Medication Use among the Elderly in the Community and Nursing Homes [377]  
Ifeanyi I Okechukwu, Kathleen Bennett, John Feely. (Ireland)

- 59 **Patients' Awareness of Medicine Indications [378]**  
Ermelindo Fontes, Sofia Couto, Zilda Mendes, Ana Miranda. (Portugal)
- 60 **Utilization of Anti-Platelet Drugs in Portugal [379]**  
Ermelindo Fontes, Sofia Couto, Jose Guerreiro. (Portugal)
- 61 **Methodological Approach To Investigate the Use of Emergency Oral Contraception in Portugal. Cross-Sectional Study in Community Pharmacies [380]**  
Ermelindo Fontes, Patricia Ferreira, Telma Costa, Ana Miranda. (Portugal)
- 62 **Utilization Review of Anti-Ulcer Drugs in Insured Outpatients [381]**  
Kheirollah Gholami, Molouk Hajibabae, Abbas Mirblouk, Hamid Khoie, Zamani Shahyad, Gloria Shalviri. (Islamic Republic of Iran)
- 63 **Short-Lived Influence on Prescribing Trends Following Publication of the ALLHAT Trial [382]**  
Patricia A Caetano, Steven G Morgan, Colette Raymond, Ken Bassett. (Canada)
- 64 **Pharmacoepidemiology of Drug Use at Clinics of University Teaching Hospital in Novi Sad, Serbia and Montenegro [383]**  
Zdenko Tomic, Ana Sabo, Zoran Bokumiric, Olga Horvat, Slavica Canak, Vida Jakovljevic. (Yugoslavia)
- 65 **Benzodiazepine's Utilization in Continental Portugal (1999-2004) [384]**  
Ines Teixeira, Claudia Furtado. (Portugal)
- 66 **Repetition of Pharmacotherapy Key Messages in a Social Marketing Program To Improve Prescribing [385]**  
Judith M Mackson, Fiona E Horn, Debra Rowett, Gwen Higgins, Lynn M Weekes. (Australia)
- 67 **Fifteen Years of Pharmaceutical Expenditures in Belgium from 1990 to 2004 [386]**  
Robert H Vander Stichele, Rudy Van Tielen. (Belgium)
- 68 **Drug Rationalization at the Clinics in University Teaching Centre Novi Sad: Introducing the Delivery of Daily Doses of the Drugs to Hospital Departments [387]**  
Ana Sabo, Zdenko Tomic, Goran Marusic, Dragan Draskovic, Jan Varga, Ivana Krajcic. (Yugoslavia)
- 69 **Emergency Oral Contraception Use Pattern in Portuguese Women [388]**  
Ermelindo Fontes, Patricia Ferreira, Telma Costa, Ana Miranda. (Portugal)
- 70 **Utilization of Statins in Portugal [389]**  
Ermelindo Fontes, Zilda Mendes. (Portugal)
- 71 **Setting a Criterion and a Standard for Prescribing Quality Indicators in Antibiotic Therapy in Ambulatory Care: Mind the Gap When Dabbling in the Dark [390]**  
Pierre Chevalier, Henk Van Den Broele, Robert H Vander Stichele, Monique M Elseviers. (Belgium)
- 72 **Non Prescription Antibiotic Use in Hungary [391]**  
Maria Matuz, Ria Benko, Peter Doro, Edit Kosik, Edit Polgar, Gyongyver Soos. (Hungary)
- 73 **Antidepressant Utilization in British Columbia, Canada [392]**  
Colette Raymond, Patricia A Caetano, Steven G Morgan. (Canada)
- 74 **Pattern of Use of Statins in Portugal [393]**  
Ermelindo Fontes, Sofia Couto, Zilda Mendes, Paula Martins, Ana Miranda. (Portugal)
- 75 **Change of Hormone Replacement Therapy Usage in Canada before and after the Publication of the Women's Health Initiative Studies [394]**  
Yipu Shi, Shi Wu Wen, Mark Walker, Chris Robinson. (Canada)
- 76 **Impact of Institutional Determinants on Prescribing Quality: Results of the PHEBE Project [395]**  
Robert H Vander Stichele, Kris Soenen, Monique M Elseviers, Micheline Gobert, Pierre Chevalier. (Belgium)
- 77 **Population Based Drug Databases in Sweden: How Representative Is the County of Jämtland as a Source of Data in Sweden? [396]**  
Ulf Bergman, Andrejs Leimanis, Michael Lundberg, Bjorn Wettermark. (Sweden)
- 78 **Appraisal and Compliance Behaviour among Patients in Lipid-Lowering Drug Treatment [397]**  
John Larsen, Lina Felde. (Denmark)
- 79 **Use and Predictors of Use of Folic Acid among Women with Self Reported Short Term Child Wish [398]**  
Willemijn M Meijer, Denhard J de Smit, Lolkje TW de Jong-van den Berg. (Netherlands)
- 80 **How We Imagine a Drug? Maximizing Placebo Effect of Active Treatments [399]**  
Ana M Macedo, Josep-E Banos, Magi Farre. (Spain)
- 81 **Exploring Desires for Information, Self-Efficacy Beliefs in Patients with Hypertension: And Other Potential Determinants for Non-Compliance [400]**  
Sofia Couto, Jose P Guerreiro, Filipa A Costa, Ana C Miranda, Catherine Duggan. (Portugal)
- 82 **Patients' Information Needs and Perceptions of Medicines and Illness: A Multi-Method Approach To Develop and Validate Measures in Portugal [401]**  
Filipa A Costa, Catherine Duggan, Ian Bates. (Portugal)
- 83 **Increased Risk of Hospitalizations Related to Acute Hepatitis in Chinese Herb Users - A Case-Crossover Study of 200,000 People Followed during 1997-2002 in Taiwan [402]**  
Chang-Hsing Lee, Jung-Nein Lai, Jung-Der Wang, Pau-Chung Chen. (Taiwan)
- 84 **The Optimal Content and Format of Prescription Drug Labels: A Systematic Review of the Literature [403]**  
William H Shrank, Jerry Avorn, Cony Rolon, Paul Shekelle. (United States)
- 85 **Utilisation and Expenditure of Lipid Lowering Drugs in Finland, Ireland and Sweden. Effect of Generic Substitution [404]**  
Jaana E Martikainen, Björn Wettermark, Lesley H Tilson. (Finland)
- 86 **Use of Administrative Data To Observe the Cost and Prescribing Patterns for Mental Health Care in a Medicaid Population [405]**  
Thomas J Bunz, Brian J Quilliam, Rita M Marcoux, E Paul Larrat. (United States)
- 87 **Physician Sources and Perceptions of Drug Risk Communication [406]**  
Elaine H Morrato, Barbara Curbow, Carolyn Nowels, Manning Feinleib. (United States)
- 88 **Factors Associated with Orphan Drug Approval [407]**  
Harald E Heemstra, Sonja van Weely, Harrie JJ Seeverens, Hans A Büller, Hubert GM Leufkens. (Netherlands)

- 89 **Does a Prior Approval Process Required for Coverage of Inhaled Combination Therapies with Corticosteroids and Long-Acting beta2-Agonists Affect Asthma Treatment?** [408]  
Line Guénette, Joëlle Mimeault. (Canada)
- 90 **The Role of Litigation in Defining Drug Risks** [409]  
Aaron S Kesselheim, Jerry Avorn. (United States)
- 91 **British Columbian Physicians' Beliefs Regarding Reference Drug and Generic Substitution Programs** [410]  
Jennifer M Polinski, Malcolm Maclure, Blair Marshall, Alan Cassels, Jessica Agnew-Blais, Amanda Patrick, Sebastian Schneeweiss. (United States)
- 92 **Impact of Sequential Pharmacy Benefit Changes on Health Outcomes in a PPO** [411]  
Thomas K Hazlet, Elizabeth B James, David K Blough. (United States)
- 93 **The Impact of Cost-Sharing on Antidepressant Use in Older Adults** [412]  
Amanda R Patrick, Sebastian Schneeweiss, Colin R Dormuth, Malcolm Maclure, Philip S Wang. (United States)
- 94 **How Do Practitioners Prescribe Drugs That Can Be Replaced by Generics in Portugal?** [413]  
José P Guerreiro, Ermelindo Fontes, Zilda Mendes. (Portugal)
- 95 **Exploring Hypothesis for Explaining Differences on Generic Prescription Profiles** [414]  
José P Guerreiro, Ermelindo Fontes, Zilda Mendes. (Portugal)
- 96 **Impact of the Exception Drug Status on Access to Clopidogrel in Quebec** [415]  
Odile Sheehy, Stéphane Rinfret, Jacques LeLorier. (Canada)
- 97 **Income-Based Drug Coverage in British Columbia: The Impact on Access to Medicines** [416]  
Patricia A Caetano, Colette Raymond, Steven G Morgan, Gillian Hanley. (Canada)
- 98 **Orphan Medicines' Therapeutic Profile** [417]  
Carla Teixeira de Barros. (Portugal)
- 99 **Sleep Disorders Are Associated with Psychiatric and Gastrointestinal Diseases in Primary Care** [418]  
Mari-Ann Wallander, Saga Johansson, Ana Ruigómez, Luis A García Rodríguez. (Sweden)
- 100 **The Role of Gastrointestinal Morbidity in Abdominal Pain** [419]  
Mari-Ann Wallander, Saga Johansson, Ana Ruigómez, Luis A García Rodríguez. (Sweden)
- 101 **Medicine Poisoning in Portugal: A Preliminary Analysis of Hospital Discharge Data** [420]  
Pedro Marques-Vidal, Sara Marques-Vidal, Carlos Matias Dias. (Portugal)
- 102 **Variability across U.S. Medicaid Prior Authorization Programs for Anti-Depressants** [421]  
Jennifer M Polinski, Philip Wang, Amber Servi, Elizabeth Robinson, Michael Fischer. (United States)
- 103 **Prescriptions of Non Steroidal Anti Inflammatory Drugs during Pregnancy in 2003-2004 in Midi-Pyrenees Area** [422]  
Caroline Hurault, Isabelle Lacroix, Robert Bourrel, Maryse Lapeyre-Mestre, Jean-Louis Montastruc, Christine Damase-Michel. (France)
- 104 **Disparities in the Use of Anti-Hypertensive Medication in a Multiethnic Population in Southern Sweden** [423]  
Farhad A Khan, Rosvall Maria, Mathias Nilsson, Per-Olof Ostergren. (Sweden)
- 105 **Performance-Enhancing Drug Use by Students during Examination Periods** [424]  
Maryse Lapeyre-Mestre, Eva Lapaix. (France)
- 106 **Osteoporosis Screening, a Health Promotion Initiative in Portuguese Community Pharmacies** [425]  
Isabel Oliveira, Sofia Figueiredo, Brenda Madureira. (Portugal)
- 107 **Impact of a Dyslipidemia Management Workshop on Community Pharmacists' Knowledge: TEAM Workshop** [426]  
Julie Villeneuve, Jacques Genest, Diane Lamarre, Marie-Claude Vanier, Sylvie Perreault, Lucie Blais, Marie-Therese Lussier, Eveline Hudon, Lyne Lalonde. (Canada)
- 108 **Effect of Isoniazid Prophylaxis for Tuberculosis in Adults with Anergy and HIV Infection: An Updated and Improved Meta-Analysis of Randomized Controlled Trials** [427]  
Huei-Ting Tsai. (United States)
- 109 **Adherence to Chronic Medication in Dutch Primary Care** [428]  
Liset van Dijk, Dinesh Somai, Eibert Heerdink, Sandra van Dulmen, Emmy Sluijs, Denise De Ridder, Jozien Bensing. (Netherlands)
- 110 **Risk of Systemic Adverse Effects and Nasal Perforation with Fluticasone Propionate as Compared to Other Inhaled Nasal Steroids** [429]  
Stephen P Motsko, Marlo A Corrao, Ruby M Vendiola, Kourtney J Davis, Earl L Goehring, Judith K Jones. (United States)
- 111 **Beyond Dispensing: What Pharmacists Do To Intervene To Improve Outcomes of Nursing Home Residents?** [430]  
Kate L Lapane, Brian J Quilliam, Carmel M Hughes. (United States)
- 112 **Is the Use of Information Technology Feasible To Exchange Information among Pharmacists Providing Care for Nursing Home Residents?** [431]  
Kate L Lapane, Carmel M Hughes, Janice L Feinberg. (United States)
- 113 **"Assessment of Hospital Pharmacies in Brazil": A Propose for Classification of Services** [432]  
Ana M Messeder, Claudia GS Osorio-de-Castro, Luiz AB Camacho. (Brazil)
- 114 **Evaluation of Cardio and Cerebrovascular Disease Risk in Portugal** [433]  
Ana Macedo, Ana Santos. (Portugal)
- 115 **Adverse Drug Reactions Suffered by University Students** [434]  
Ramona Mateos-Campos. (Spain)
- 116 **Modernisation of the Statutory Health Insurance Act in Germany - Does It Influence Sex-Specific Prescribing Characteristics from 2003 to 2005?** [435]  
Katrin Janhsen, Gerd Glaeske. (Germany)
- 117 **The Relation between the Use of Psychoactive Substances and Injury Severity within a Group of Crash Involved Drivers** [436]  
Beitske E Smink, Kris LL Movig, Klaas J Luthof, Johan J De Gier, Donald RA Uges, Antoine CG Egberts. (Netherlands)
- 118 **Health Care Utilization of Patients with Chronic Low Back Pain in Germany. A Study Based on Administrative Health Care Data** [437]  
Ingrid Schubert, Ingrid Koester, Peter Ihle. (Germany)

- 119 Diabetes Pharmacoepidemiology Approach to Complications and Overall Costs through Case-Control Methodology [438]**  
Claudio Voci, Luca Demattè, Elisa Rossi, Alessandra Berti, Marisa De Rosa. (Italy)
- 120 Epidemiology, Treatment, and Costs of Osteoporosis in Germany – The BoneEVA-Study [439]**  
Sandra Mangiapane, Holger Gothe, Ariane Höer, Bertram Häussler. (Germany)
- 121 Clinical Trials and Nails [440]**  
Javier Cid Ruzafa, Ana M Rueda de Castro, William L Holden. (Spain)
- 122 Inappropriate Benzodiazepine Use in Older Adults and the Risk of Fracture [441]**  
Cornelis S van der Hooft, Mariette W Schoofs, Gijsbertus Ziere, Albert Hofman, Huibert A Pols, Miriam C Sturkenboom, Bruno H Stricker. (Netherlands)
- 123 Relationships between Full-Fill Rate of Quality Indicators of Pharmacologic Therapy and Mortality of Patients with Acute Myocardial Infarction in a Medical Center [442]**  
Chen-fang Lin, Chun-yu Wang. (Taiwan)
- 124 A Cost-Effectiveness Analysis (CEA) of 3 Interventions To Enhance Medication Laboratory Monitoring [443]**  
David H Smith, Adrienne Feldstein, Nancy Perrin, Xiuhai Yang, Rix Mary, Marsha Raebel, David Magid, Steven Simon, Stephen Soumerai. (United States)
- 125 Health Outcomes of High Cost Pharmaceutical Users [444]**  
Anita L Kozyrskyj, Matthew E Dahl, Songul Bozat. (Canada)
- 126 Does the Introduction of an Incentive Based Contract Ensure Equity of Treatment of Patients with Stroke in Scottish Primary Care? [445]**  
Colin R Simpson, Philip C Hannaford, Karen Lefevre, David Williams. (United Kingdom)
- 127 European Surveillance of Antimicrobial Consumption (ESAC): Quality Indicators of Antibiotic Prescribing in Ambulatory Care [446]**  
Matus Ferech, Samuel Coenen, Erik Hendrickx, Carl Suetens, Surbhi Malhotra-Kumar, Herman Goossens, ESAC Project Group. (Belgium)
- 128 QUADRI: A National Survey of the Quality of Care for Diabetic Persons in Italy [447]**  
Marina Maggini, Valerio Aprile, Sandro Baldissera, Angelo D'Argenzio, Salvatore Lopresti, Oscar Mingozzi, Salvatore Scondotto, Alberto Perra, Yllka Lodra, Bruno Caffari, Nancy Binkin. (Italy)
- 129 Prospective Observational Study of Adverse Drug Reactions (ADR) in an Internal Medicine Department [448]**  
Luis S Pinheiro, Vasco AJ Maria, Margarida Lucas, Rui MM Victorino. (Portugal)
- 130 The Impact of Revised Practice Guidelines on Prescribing Drugs in the Treatment of Type 2 Diabetes Mellitus [449]**  
Rene Lub, Petra Denig, Paul van den Berg, Klaas Hoogenberg, Lolkje de Jong-van den Berg. (Netherlands)
- 131 Use of Indicators To Evaluate the Quality of Care in Hospitalized Adults with Community-Acquired Pneumonia [450]**  
S A Ratchina, E P Shal, A S Frolova, S A Guljaeva. (Russian Federation)
- 132 Influence of Generic Substitution on Drug Sales Pattern [451]**  
Karolina Andersson, Max G Petzold, Peter Allebeck, Anders Carlsten. (Sweden)
- 133 The Impact of Medicinal Authority's Warnings on the Prescribing of SSRI Antidepressants to Children and Adolescents in Norway [452]**  
Jørgen G Bramness, Anders Engeland, Kari Furu. (Norway)
- 134 Quality Assessment of ADR-Reports on Generic Substitution Related to Early Signal Identification [453]**  
Anne Bee Hegge, Linda Amundstuen, Anna Lillefloth, Hanne Stenberg-Nilsen, Pernille Harg. (Norway)
- 135 Rationalization of Pharmaceuticals Utilization by Means of Drug Formulary: The Pilot Project in Belarussian Multiprofile Hospital [454]**  
Maxim N Mily, Marina M Sacheck, Vladimir Y Lugovoy, Sergey A Golubev. (Belarus)
- 136 A Way To Improve Compliance with an Osteoporosis Treatment: Setting up of a Patient Education Program [455]**  
Christian Roux, Bernard Cortet, Stephanie Tcherny-Lessenot, Priscille Poitral, Soyi Liu-Leage. (France)
- 137 Utilisation of Anti-Rheumatic Drugs in Australia: Impact of Introducing High-Cost Biologics under the Pharmaceutical Benefits Scheme [456]**  
Christine Y Lu, Ken M Williams, Ric O Day. (Australia)
- 138 Access to High-Cost Medicines for the Treatment of Rheumatoid Arthritis under Australia's Pharmaceutical Benefits Scheme [457]**  
Christine Y Lu, Ken M Williams, Ric O Day. (Australia)
- 139 Postmarket Surveillance of Drug-Eluting Stents [458]**  
Hesha J Duggirala, David E Kandzari, Thomas P Gross. (United States)
- 140 Are Drugs a Risk Factor for Heat-Related Hospitalisation? [459]**  
Karin Martin, Marie-Pierre Goumy, Claude Gabinsky, Isabelle Faure, Bernard Begaud, Philippe Latry, Helene Verdoux. (France, Metropolitan)
- 141 Comparison of Data from a US National Survey (NHANES) with Data from a Cohort Recruited from the Internet [460]**  
Alicia Gilsenan, Xiaolei Zhou, Florence Coste, Amanda Allshouse. (United States)
- 142 Rosuvastatin Similar to Other Statins with Respect to Muscle-Related, Renal, and Hepatic Adverse Events [461]**  
Andrew T McAfee, Eileen E Ming, John D Seeger, Sherry G Quinn, Eva W Ng, Jared D Danielson, Jennifer A Cutone, Jonathan C Fox, Alexander M Walker. (United States)
- 143 Risk of Intraocular Injection-Related Endophthalmitis in Patients with Age-Related Macular Degeneration (AMD) in the US Medicare Population [462]**  
Jingping Mo, Yinkang Duan, Manju Patel, Ronald Klein, Ingrid U Scott, Kui Huang, Duanping Liao. (United States)
- 144 Use of Herbal/Natural Supplements According to Racial/Ethnic Group [463]**  
Judith P Kelly, David W Kaufman, Lynn Rosenberg, Allen A Mitchell. (United States)
- 145 Use of the Registry Methodology in a Rare Disease Setting: The Familial Adenomatous Polyposis (FAP) Registry-Based Study [464]**  
L Gutiérrez, E Moy, C Eagle. (Spain)

- 146 A New Register on Prescribed Pharmaceuticals in Sweden [465]  
 Andrejs Leimanis, Björn Wettermark, Niklas Hammar, Michael Fored, Petra Otterblad Olausson, Måns Rosén. (Sweden)
- 147 Pharmacovigilance Regional Centres – The Suitable Model for Small Countries? [466]  
 S Gonçalves, A Araújo, M Lemos, S Queiroz, E Teófilo, J R Silva, R Carmona. (Portugal)
- 148 Extent of Pharmacoepidemiology Education in U.S. Schools of Pharmacy [467]  
 Esmund D Nwokeji, Karen L Rascati, Tish R Moczygemba, James P Wilson. (United States)
- 149 Intervention with Outreach Visits To Change Prescription Patterns in General Practice in the County of Aarhus, Denmark [468]  
 Pia Ehlers, Inger Kristiansen, Jørgen N Nielsen, Hanne Nielsen, Jens Søndergaard. (Denmark)
- 150 Quantifying the Amount and Cost of Wasted Medicines in Portugal [469]  
 Sofia Crisostomo, Zilda Mendes, Francisco Batel Marques, Ana Paula Martins, Vitor Rodrigues, Carlos Fontes Ribeiro. (Portugal)
- 151 Refill Persistence with Oral Antidiabetic Therapy in Hungary [470]  
 Peter Doro, Ria Benko, Edit Kosik, Maria Matuz, Katalin Toth, Gyongyver Soos. (Hungary)
- 152 Cardiovascular Risk Factors in Patients Diagnosed with Stage III or IV Breast Cancer Treated with Cardiotoxic and Non-Cardiotoxic Regimens [471]  
 Marianne Ulcickas Yood, Annette Beiderbeck, Jacquelyn Saltzgeber, Susan A Oliveria. (United States)
- 153 Verification of Observational Data Using GPRD [472]  
 Tim J Williams, Tarita Murray-Thomas, Brendon Ambersley. (United Kingdom)
- 154 The Direct Relationship between Childhood Health and Elderly Self-Rated Health [473]  
 Mark A Allen. (United States)
- 155 Assessment of Exposure to the Excipients Benzyl Alcohol (BA) and Propylene Glycol (PG) in Critically Ill Neonates [474]  
 Nadine Shehab, Carrie L Mulvahill, Darcie D Streetman. (United States)

◀ END SESSION B



**Evidence Matters**

Never before has the **value** of pharmaceuticals, biotechnology, and medical devices been challenged with such intensity and frequency. **At UBC we believe the most credible proof of value is scientific evidence.** We deliver evidence to demonstrate product effectiveness, minimize safety risks, and document economic benefits.

late-stage clinical trials • large-streamlined studies • product registries • epidemiology & risk management consulting • real world studies  
 disease registries • longitudinal observational studies • outcomes research • health economics & policy • systematic reviews & meta-analyses  
 data resources & analytics • pricing & reimbursement • training & education • investigator services • patient programs • life sciences training  
 electronic data capture • IVR and web systems for clinical research • automated randomization • electronic patient diaries • inventory management

UBC Speakers at the 22nd Annual ICPE Meeting:  
 • Gerald A. Faich, MD, MPH, FISPE, "Role and Design of Large Streamlined Trials"  
 • Matt Reynolds, PhD, and Shubh Sethi, MBA, "How to Design an Effective Presentation for Your Internal and External Stakeholders"

[www.unitedbiosource.com](http://www.unitedbiosource.com)

**UBC**

© 2006 United Biosource Corporation

- 1 **All-Cause Mortality Associated with Atypical and Typical Antipsychotics in Demented Outpatients: A Population-Based Study [475]**  
Gianluca Trifirò, Katia MC Verhamme, Gijsbertus Ziere, Achille P Caputi, Bruno HCh Stricker, Miriam CJM Sturkenboom. (Italy)
- 2 **Fatal Reports in Intramuscular vs Oral Antipsychotics in the FDA Adverse Event Reporting System (AERS) [476]**  
Sebastian Sorsaburu, Karen E Chilcott, F Patrick DeLisle, Kenneth Hornbuckle. (United States)
- 3 **Has the Warning Issued in 2003 on Increased Risk of Suicide Associated with SSRI Use Had an Impact on Current Antidepressant Users? [477]**  
Louise Barnard. (Canada)
- 4 **Venous Thromboembolism during Treatment with Antipsychotics [478]**  
Olav Spigset, Andrew Bate, Malin Ståhl, Staffan Hägg. (Norway)
- 5 **Identification of Patients with Rheumatoid Arthritis Using Drug Database Data [479]**  
Marie-Agnes Bernard, Patrick Blin, Bernard Begaud, Abdellilah Abouelfath, Nicholas Moore, Annie Fourrier, The CADEUS Study Team. (France)
- 6 **Efficiency and Relative Power of Nested Case-Control Studies [480]**  
Alex D McMahon. (United Kingdom)
- 7 **A Comparison of Two Multiple Characteristics Decision Making Techniques for the Comparison of Antihypertensive Drugs: Simple Additive Weighting and Technique for Order Preference by Similarity to an Ideal Solution [481]**  
Boris LG Van Wijk, Olaf H Klungel, Eibert R Heerdink, Anthonius De Boer. (Netherlands)
- 8 **Methodologic Lessons Learned in a Cluster-Randomized Trial of an Intervention To Improve Hypertension Control [482]**  
Sean Hennessy, Charles E Leonard, Wei Yang, Stephen E Kimmel, Raymond R Townsend, Alan G Wasserstein, Thomas R Ten Have, Warren B Bilker. (United States)
- 9 **Risk-Benefit Analysis of Rofecoxib Versus Naproxen for the Treatment of Rheumatoid Arthritis Patients: A Discrete Event Simulation [483]**  
Larry D Lynd, Carlo A Marra, Mehdi Najafzadeh, Mohsen Sadatsafavi. (Canada)
- 10 **Use of Selective Serotonin Inhibitors and Risk of Hip/Femur Fractures: A Population-Based Case-Control Study [484]**  
Brahm Thio, Frank de Vries, Antoine CG Egberts, Bert GM Leufkens, Tjeerd P van Staa. (Netherlands)
- 11 **Long-Term Use of Selective Serotonin Reuptake Inhibitor Antidepressants Is Associated with Increased Risk of Non-Vertebral Fractures [485]**  
Gijsbertus Ziere, Jeanne P Dieleman, Tischa JM van der Cammen, Albert Hofman, Huibert AP Pols, Bruno HCh Stricker. (Netherlands)
- 12 **Persistence of Antidepressant Use in Finland: A Register-Linkage Study, 1994-2003 [486]**  
Sinikka Sihvo, Tiina Sevón, Jari Haukka, Elina Hemminki, Ilmo Keskimäki, Sonja Lumme, Alison McCallum, Kristian Wahlbeck. (Finland)
- 13 **Meta-Analysis of Adverse Effects in Placebo Controlled Studies with Paroxetine [487]**  
Ivar Aursnes. (Norway)
- 14 **Comparison of Hospital Readmission Rates in Patients with Acute Myocardial Infarction Stratified by Antidepressant Use [488]**  
Christopher M Blanchette, Stephen Stenkowski, Christopher Craver, William B Saunders. (United States)
- 15 **Effects of Fluvoxamine, Fluoxetine and Placebo on Psychomotor Performance in Healthy Volunteers [489]**  
Emanuel Ponciano, Margarida Pocinho, Elisabete Moita, Helena Monteiro, Ian Indmarch. (Portugal)
- 16 **Prescribing of Tricyclic Antidepressants and Selective Serotonin Re-Uptake Inhibitors in Children and Adolescents in South Africa [490]**  
Kristien Van Schalkwyk, Ilse Truter. (South Africa)
- 17 **Behavioural Toxicity of Mianserin and Fluoxetine [491]**  
Helena Jardim, Emanuel Ponciano, Ian Hindmarch. (Portugal)
- 18 **Revisited Effects on Psychomotor Functions of Clobazam and Diazepam – A Double-Blind Study [492]**  
Helena Jardim, Emanuel Ponciano, Ian Hindmarch. (Portugal)
- 19 **Differences in Benzodiazepine Prescribing in South Africa between 1996 and 2004 [493]**  
Ilse Truter, Theunis JvW Kotze. (South Africa)
- 20 **Outpatient Utilization of Benzodiazepines in Croatia 2001-2004: Comparison with Scandinavian Countries [494]**  
Danijela Stimac, Josip Culig, Ivan Vukusic, Zvonimir Sostar, Sinisa Tomic. (Croatia)
- 21 **Positive Predictive Value of ICD-9 Code 411 in the Identification of Cases of Acute Coronary Syndrome in the Saskatchewan Hospital Database [495]**  
C Varas-Lorenzo, MR Stang, L Tomas, V Gimeno, J Castellsague, S Perez-Gutthann. (Spain)
- 22 **Validity of ICD9-Codes for Upper Gastrointestinal Bleeding in the Saskatchewan Health Databases [496]**  
V Gimeno, M Bernat, MR Stang, J Aguado, J Castellsague, S Perez-Gutthann. (Spain)
- 23 **Validity of Hospital Discharge ICD Codes for Identifying Patients with Thrombocytopenia [497]**  
Maarten J ten Berg, Albert Huisman, Patricia MLA van den Bemt, Alfred FAM Schobben, Antoine CG Egberts, Wouter W van Solinge. (Netherlands)
- 24 **Contribution of the Different Medical Record Sources to the Drug Use Information: Analysis Using the Rochester Epidemiology Project (REP) Integrated Medical Record System [498]**  
Paulo J Nicola, Hilal Maradit-Kremers, Megan S Reinalda, Cynthia S Crowson, Sherine E Gabriel. (United States)
- 25 **Estimating Period Prevalence Using Censored Data [499]**  
John W Logie, Maurille A Feudjo-Tepie. (United Kingdom)
- 26 **Development and Validation of Database Measures of Asthma Severity and Control [500]**  
Faranak Firoozi, Catherine Lemiere, Marie-France Beauchesne, Amelie Forget, Lucie Blais. (Canada)
- 27 **Validation Studies of the Health Improvement Network (THIN) Database for Pharmacoepidemiology Research [501]**  
James D Lewis, Rita Schinnar, Warren B Bilker, Xingmei Wang, Brian L Strom. (United States)
- 28 **Quality Assurance Analyses of Data from Five Large US Medicaid Programs [502]**  
Sean Hennessy, Charles E Leonard, Craig Newcomb, Warren B Bilker. (United States)

- 29 **Does the Generic Formulation of the beta-Blocker Metoprolol Carry a Higher Risk for Hospitalization Than the Originator?** [503]  
Wolfgang Ahrens, Bernd Muehlbauer, Juergen Timm, Iris Pigeot. (Germany)
- 30 **Angiotensin II Receptor Blockers (ARB), Hypertensive Treatments, and the Risk of Myocardial Infarction: A Systematic Review of the Literature** [504]  
Matthew W Reynolds, Brian Sercus, Janet Claflin, Allen Feldman. (United States)
- 31 **Effects of Antihypertensive Drug Treatments on Fracture Outcomes: A Meta-Analysis of Observational Studies** [505]  
Matthew Wiens, Mahyar Etmian, Sudeep Gill, Bahi Takkouche. (Canada)
- 32 **Erectile Dysfunction in Males Treated with Antihypertensive Drugs. A Review of Spontaneous Reports in the Swedish and WHO Adverse Drug Reaction Databases** [506]  
Elisabet Ekman, Viktoria Werkstrom, Petter Hedlund. (Sweden)
- 33 **Effect of Concomitantly Used CYP-3A4 Inhibitors in Patients Treated with Calcium Channel Blockers** [507]  
Takeshi Mayama, Toshiharu Fujita, Masanori Yoshida, Takuyuki Matsumoto. (Japan)
- 34 **Incidence of Diabetes in Users of Antipsychotics in Australia** [508]  
Richard L Hill, Ian W Boyd, Lisa J Calcino, Robert L Walsh, Judy Zhang. (Australia)
- 35 **Prescribing Patterns in Chronic Psychiatric Patients** [509]  
Susanne G Schorr, Anton JM Loonen, Jacobus RBJ Brouwers, Katja Taxis. (Netherlands)
- 36 **Pain Management in Patients under Opiate Maintenance Treatment** [510]  
Maryline Desplas, Anne Roussin, Maryse Lapeyre-Mestre. (France)
- 37 **Use of Antidepressants in an Urban Sample of Portuguese Adults** [511]  
Joana Bastos, Raquel Lucas, Ana Azevedo, Henrique Barros. (Portugal)
- 38 **Drug Diversion in Community Pharmacies in France: Profiles of Suspect Prescriptions Observed in the National Survey OSIAP (Ordonnances Suspectes Indicateur d'Abus et de Pharmacodependance) 2001-2004** [512]  
Olivia Boeuf, Maryse Lapeyre-Mestre, French Network of CEIP. (France)
- 39 **Patient Reports on Discontinuation of Antidepressants** [513]  
Katja van Geffen, Rolf van Hulten, Marcel Bouvy, Eibert R Heerdink, Antoine CG Egberts. (Netherlands)
- 40 **The Risk of Ischemic Stroke Associated with COX-2 Selective NSAID Use – A Nested Case Control Study** [514]  
Frank Andersohn, René Schade, Samy Suissa, Edeltraut Garbe. (Germany)
- 41 **Serious Skin Reactions and COX-2 Inhibitors: A Case Series from Prescription-Event Monitoring (PEM) in England** [515]  
Deborah Layton, Vanessa Marshall, Andrew Boshier, Peter Friedmann, Saad Shakir. (United Kingdom)
- 42 **Acetaminophen and Non-Steroidal Anti-Inflammatory Drug Use and Risk of Incident Hypertension in Apparently Healthy Women** [516]  
Tobias Kurth, Julie E Buring, J Michael Gaziano. (United States)
- 43 **Factors Associated with Gastroprotective Agent Usage Pattern in NSAIDs Users: A Multinomial Analysis in the CADEUS Study** [517]  
Regis Lassalle, Jacques Benichou, Fanny Depont, Nicholas Moore, Cecile Droz, Michel Amouretti, Patrick Blin, Annie Fourier, The CADEUS Study Team. (France)
- 44 **Did the Withdrawal of Rofecoxib Impact on Prescribing Trends of Non-Steroidal Anti Inflammatory / Analgesic Drugs?** [518]  
Kathleen Bennett, Mary Teeling, John Feely. (Ireland)
- 45 **NSAID Use Is Associated with Lower Mammographic Breast Density in Younger Women** [519]  
Tamarra James, Mary Beth Terry, Amy Trentham-Dietz, Diana SM Buist. (United States)
- 46 **Risk of Lung Cancer among Users of Non-Steroidal Anti-Inflammatory Drugs** [520]  
Sonia Hernández-Díaz, Luis A García Rodríguez. (United States)
- 47 **Quantitative Assessment of the Gastrointestinal and Cardiovascular Risk-Benefit of Celecoxib Compared to Individual NSAIDs at the Population Level** [521]  
C Varas-Lorenzo, A Maguire, J Castellsague, S Perez-Gutthann. (Spain)
- 48 **Use of Selective COX-2-Inhibitors in Norway before and after the Withdrawal of Rofecoxib – Norwegian Prescription Database** [522]  
Kari Furu, Svetlana Skurtveit, Lars Slørdal. (Norway)
- 49 **Who Were the New COX-2 Users in CADEUS?** [523]  
Cecile Droz, Nicholas Moore, Fanny Depont, Michel Amouretti, Patrick Blin, Annie Fourier, The CADEUS Study Team. (France)
- 50 **Safety Profile of Etoricoxib in General Practice in England: Results of a Prescription-Event Monitoring Study** [524]  
V Marshall, L Wilton, S Shakir. (United Kingdom)
- 51 **Prescribing Patterns of Anti-Migraine Drugs in a Primary Care Patient Population** [525]  
Ilse Truter. (South Africa)
- 52 **Exploring the Use of Analgesics and Nutritional Supplements by Patients with Knee Pain** [526]  
Garry R Barton, Anthony J Avery, Tracey H Sach, Claire Jenkinson, Kenneth R Muir. (United Kingdom)
- 53 **Pain Management Pattern on Cancer Patients** [527]  
Hwa J Kim, Nam-kyong Choi, Sun-young Jung, Joo-young Kim, Byung-Joo Park. (Korea)
- 54 **Statins and the Risk of Lung, Breast and Colorectal Cancer** [528]  
Soko Setoguchi, Robert J Glynn, Jerry Avorn, Helen Mogun, Sebastian Schneeweiss. (United States)
- 55 **Impact of Statin Adherence on Non Fatal Coronary Artery Disease (CAD) among Patients for Primary Prevention** [529]  
Sylvie Perreault, Alice Dragomir, Lucie Blais, Lyne Lalonde, Anick Bérard, Michel White. (Canada)
- 56 **Impact of Statin Adherence on Non Fatal Stroke among Patients for Primary Prevention** [530]  
Sylvie Perreault, Alice Dragomir, Lucie Blais, Lyne Lalonde, Anick Bérard, Robert Côté. (Canada)

- 57 **Acute Effects of Discontinuation of Statin Treatment on the Occurrence of a First Myocardial Infarction [531]**  
Aukje K Mantel-Teeuwisse, Menno E van der Elst, Olaf H Klungel, Marcel L Bouvy, Cornelis J de Blaey, Anthonius de Boer. (Netherlands)
- 58 **Rosuvastatin's Safety Profile Is Comparable to That of Other Marketed Statins: Results from a Historical Cohort Study in More Than 45,000 Dutch Statin Users [532]**  
Wim G Goetsch, Edith Heintjes, John JP Kastelein, Saga Johansson, Ron MC Herings. (Netherlands)
- 59 **Adherence to Statin Therapy in Patients Who Persist with Treatment [533]**  
Thomas I Barron, Kathleen Bennett, John Feely. (Ireland)
- 60 **Role of Medication in Patient's Revisits at the Montreal Heart Institute Emergency Department [534]**  
Vincent Raymond, Alain Vadeboncoeur, Wendy Kennedy, Claudine Laurier. (Canada)
- 61 **Prescribing of Statins in Norway after New Reimbursement Regulations in 2005 – Data from the Norwegian Prescription Database (NorPD) [535]**  
Solveig Sakshaug, Kari Furu, Svetlana Skurtveit, Marit Rønning. (Norway)
- 62 **High Dose Statin Prescribing after the PROVE-IT, REVERSAL and TNT Studies [536]**  
Thomas I Barron, Kathleen Bennett, John Feely. (Ireland)
- 63 **Incidence of Severe Myositis in Patients Treated with Lipid-Lowering Drugs [537]**  
Ju Young Kim, Byung Joo Park. (Republic of Korea)
- 64 **Interrelation between Antihypertensive Medication Use and CVD Lifestyle Risk Factor Modification [538]**  
C Ineke Neutel, Norm RC Campbell. (Canada)
- 65 **Hypercholesterolemia and Hypertension Management in Type 2 Diabetes Patients between 1998–2003: Longitudinal Observational Study [539]**  
Jacoba P Greving, Petra Denig, Dick de Zeeuw, Henk JG Bilo, Flora M Haaijer-Ruskamp. (Netherlands)
- 66 **Should Post-MI Patients Receive Secondary Prevention Medications for Free? An Empirical Policy Analysis [540]**  
Niteesh K Choudhry, Jerry Avorn, Sebastian Schneeweiss, William H Shrank. (United States)
- 67 **Population-Based Study: Adherence Level of Antihypertensive Agents (AH) on Non Fatal Strokes [541]**  
Sylvie Perreault, Alice Dragomir, Lucie Blais, Lyne Lalonde, Anick Bérard, Robert Côté. (Canada)
- 68 **Statin Prescribing in British Columbia, Canada [542]**  
Colette B Raymond, Steven G Morgan, Patricia A Caetano. (Canada)
- 69 **Adherence to Chronic Cardiovascular Therapies: Persistence over the Years and Dose Coverage [543]**  
Elisabetta Poluzzi, Petar Strahinja, Antonio Vargiu, Maria Chiara Silvani, Domenico Motola, Alberto Vaccheri, Fabrizio De Ponti, Giulio Marchesini Reggiani, Nicola Montanaro. (Italy)
- 70 **Lipid Lowering Therapy in the Prevention of Age Related Macular Degeneration: A Meta-Analysis of Observational Studies [544]**  
Matthew Wiens, Jean Chuo, David Maberly, Mahyar Etminan. (Canada)
- 71 **Population-Based Study: Adherence Level of Antihypertensive Agents (AH) on Coronary Artery Disease (CAD) [545]**  
Sylvie Perreault, Alice Dragomir, Lucie Blais, Lyne Lalonde, Anick Bérard, Michel White. (Canada)
- 72 **10 Year Coronary Artery Disease Risk (RCAD) Reduction after Treatment with Ezetimibe 10mg/Day Co-Administered with Statins in Patients with Primary Hypercholesterolemia That Have Not Reached Target LDL-C Levels While on Statin Monotherapy [546]**  
Stéphane Bissonnette, Rafik Habib, Stella Boukas, John Sampalis. (Canada)
- 73 **Cardiovascular Drug Utilization in Portugal (2000–2004) [547]**  
Claudia Furtado, Ines Teixeira. (Portugal)
- 74 **Persistence with Statin Therapy in British Columbia, Canada [548]**  
Colette B Raymond, Patricia Caetano, Steve Morgan, Anita Kozyrskyj, Alan Katz. (Canada)
- 75 **Prevalence, Awareness, Treatment and Control of Hypertension in the Portuguese General Population [549]**  
Ana Azevedo, Raquel Lucas, Henrique Barros. (Portugal)
- 76 **Adherence to EPA Was Important in Receiving the Clinical Benefit for Hypercholesterolemia [550]**  
Hideki Origasa, Masunori Matsuzaki, Yuji Matsuzawa, Yasushi Saito, Mitsuhiro Yokoyama. (Japan)
- 77 **Comparison of Statin Use in Three Norwegian Counties in 2004 – An Individualised Prescription Database Study [551]**  
Ingeborg Hartz, Sakshaug Solveig, Furu Kari, Engeland Anders, Eggen E Anne, Njølstad Inger, Skurtveit Svetlana. (Norway)
- 78 **Consumption of Statins in the Republic of Tatarstan (Russia) [552]**  
Lilia E Ziganshina, Eugenia A Atsel, Lilia N Muhamadullina, Albert S Galyavich. (Russian Federation)
- 79 **Higher Persistence with Valsartan Compared to Enalapril in Daily Practice [553]**  
Satu J Siiskonen, Nancy S Breekveldt-Postma, Gábor Vincze, Zeba M Khan, Joëlle A Erkens, Ron MC Herings. (Netherlands)
- 80 **A Potential Protective Effect of Topical Calcineurin Inhibitors with Respect to Non Melanoma Skin Cancer [554]**  
David J Margolis, Ole Hofstad, Warren Bilker. (United States)
- 81 **Cardiovascular Risk Factors and Occurrence of Cardiovascular Adverse Events in Patients with Advanced Breast Cancer Receiving Chemotherapy [555]**  
Nancy N Breekveldt-Postma, Myrthe PP Sukel, Joelle A Erkens, Paul D van der Linden, Annette B Beiderbeck, Ron MC Herings. (Netherlands)
- 82 **Bone Metastatic Disease from Breast Cancer – Treatment with Bisphosphonates in Czech Republic Versus International Guidelines [556]**  
Veronika Vokata, Ales Kubena, Jiri Vlcek. (Czech Republic)
- 83 **Cancer Risks Associated with Antidiabetic Agents [557]**  
Carol E Koro, Steven J Barrett, Nawab Qizilbash. (United States)


- 84 **Study of Survival and Estimated Prevalence of Cancer of the Renal Parenchyma in France [558]**  
Arlette Danzon, Carolle Langlois, Pascale Grosclaude, Marc Colonna, Patricia Delafosse, E Martin, Florence Molinié, Brigitte Trétarre, Michel Velten, Fleur Levrat. (France)
- 85 **Incidence in 2000 of Cancer of the Renal Parenchyma in France [559]**  
Arlette Danzon, Carolle Langlois, Pascale Grosclaude, Michel Velten, Brigitte Trétarre, Florence Molinié, E Martin, Patricia Delafosse, Marc Colonna, Fleur Levrat. (France)
- 86 **Upgraded to Oral Presentation [560]**
- 87 **Antipsychotic Treatment Discontinuation in the Outpatient Treatment for Schizophrenia: French Results from the Pan European Soho Study [561]**  
Isabelle Gasquet, Stephanie Tcherny-Lessenot, Florence Chartier, Jean-Pierre Lepine. (France)
- 88 **Isotretinoin and the Risk of Depression in Patients with Acne: A Case-Crossover Study [562]**  
Laurent Azoulay, Lucie Blais, Anick Bérard. (Canada)
- 89 **A Case Series of Progressive Multifocal Leukoencephalopathy in an Insured Population [563]**  
P Mona Eng, Bruce R Turnbull, Suzanne F Cook, Julie E Davidson, Tobias Kurth, John D Seeger. (United States)
- 90 **Epidemiology and Treatment of Neuropathic Pain in Primary Care [564]**  
Jeanne P Dieleman, Joost Kerklaan, Daan Caudri, Vincent Scholtes, Miriam C Sturkenboom. (Netherlands)
- 91 **Do COX-2 Inhibitors Prevent Deterioration of Schizophrenia? A Nested Case-Control Study [565]**  
Pieter Stolk, Patrick C Souverein, Iain D Tatt, Antoine CG Egberts, Hubert GM Leufkens, John G Weil, Eibert R Heerdink. (Netherlands)
- 92 **Cerebral Symptoms after Treatment with Isotretinoin [566]**  
B Werner, I Buajordet, S Madsen. (Norway)
- 93 **The Incidence of Diagnosed Progressive Multifocal Leukoencephalopathy (PML) in the General Insured Population, an Insured Cohort with Multiple Sclerosis (MS) and an Insured Cohort with Crohns Disease (CD) [567]**  
Adam T Linke, Chanchal Bains, David J Webb, Suzanne F Cook, Luis C Sanin, Julie E Davidson. (United Kingdom)
- 94 **Comparing Insulins: People Using Human Insulin Are the Least Likely To Switch [568]**  
Annie Hutchison, David Russel-Jones, Corinne S de Vries. (United Kingdom)
- 95 **Comparing Insulins: No Difference in Likelihood of Serious Adverse Events in Type II Diabetes after Starting on Animal, Human or Analogue Insulin [569]**  
Annie Hutchison, David Russel-Jones, Corinne S de Vries. (United Kingdom)
- 96 **Rates and Risks of Starting Insulin in Diabetes Mellitus Type 2 Patients [570]**  
Miriam C Sturkenboom, Jeanne P Dieleman, Johan van der Lei. (Netherlands)
- 97 **Introduction of COX-2 Inhibitors Did Not Change Hospitalization Rates of Bleeding and Perforated Peptic Ulcer in Denmark [571]**  
Steffen Christensen, Mette Norgaard, Anders Riis Riis, Reimar W Thomsen, Henrik T Sorensen. (Denmark)
- 98 **Hepatitis Associated with Herbal Preparations [572]**  
Francesca Menniti-Ippolito, Carmela Santuccio, Fabio Firenzuoli, Gabriela Mazzanti, Paola Moro, Andrea Valeri, Roberto Raschetti. (Italy)
- 99 **Tegaserod Is Modestly Effective but Safe for Treatment of Irritable Bowel Syndrome or Chronic Constipation. A Meta-Analysis of Randomized Trials [573]**  
Janet Martin, Marc Bardou. (France)
- 100 **The Impact of Cancer on the Short Term Outcome of Oral Glucocorticoid Use after Peptic Ulcer Bleeding [574]**  
Marianne Rhode, Anders Riis, Steffen Christensen, Mette Norgaard, Reimar W Thomsen, Henrik T Sorensen. (Denmark)
- 101 **NSAIDs and the Risk of Upper Gastro-Intestinal Events: A Nested Case-Control Study [575]**  
Katia MC Verhamme, Georgio Mosis, Jeanne P Dieleman, Johan van der Lei, Bruno HCh Stricker, Miriam CJM Sturkenboom. (Netherlands)
- 102 **Persistence and Adherence to Proton Pump Inhibitors in Daily Clinical Practice [576]**  
Eva M van Soest, Peter D Siersema, Jeanne D Dieleman, Miriam CJM Sturkenboom, Ernst J Kuipers. (Netherlands)
- 103 **Incidence and Risk Factors for Intestinal Ischemia [577]**  
Consuelo Huerta, Miguel A Montoro, Belen Sanchez, Elena Rivero, Fabio Lievano, Luis A Garcia-Rodriguez. (Spain)
- 104 **Quality of Pharmacist-Managed Anticoagulation Service: A Randomized Controlled Trial [578]**  
Lyne Lalonde, Josee Martineau, Normand Blais, Martine Fournier, Djamal Berbiche, Marie-Claude Vanier, Lucie Blais, Sylvie Perreault, Isabel Rodrigues, Martine Montigny, Jeffrey Ginsberg. (Canada)
- 105 **Abstract Withdrawn [579]**
- 106 **Range Restriction May Reduce Bias in Stratified Propensity Score Analyses: Simulation Results Based on Uniform Effects [580]**  
Til Stürmer, Sebastian Schneeweiss, Kenneth J Rothman, Jerry Avorn, Robert J Glynn. (United States)
- 107 **Projections of the Prevalence of Chronic Myelogenous Leukaemia in the EU: Impact on Its Orphan Status [581]**  
Katarzyna Sablinska, Carles Blanch, Ana Rueda. (United States)
- 108 **Incidence of Myocardial Infarction and Cerebrovascular Accidents in Patients with Wet Age-Related Macular Degeneration in a Commercially Insured Population [582]**  
Earl Goehring, Jr., Bao-Anh Nguyen-Khoa, Winifred Werther, Pavel Napalkov, Judith K Jones. (United States)
- 109 **A Study of the Association between Hypothyroidism and Open-Angle Glaucoma in an Elderly Population [583]**  
Stephen P Motsko, Judith K Jones. (United States)

- 110 Blood Pressure Lowering Thresholds and Stroke [584]**  
Nawab Qizilbash, Adrian Mander, Maurille Feudjo-Tepie, Nada Boudiaf. (United Kingdom)
- 111 Incidence Rates of Hospitalization-Associated Bone Fractures in Dialysis Patients in the United States Renal Data System [585]**  
Victor Gastanaga, Sean Zhao, Nina Stuccio-White, Atsuko Shibata. (United States)
- 112 Cardiovascular Outcomes in a Large Cohort of Patients with Treated Hypertension: A Demonstration Study [586]**  
Andrew T McAfee, Joan Landon, Donnie Funch, Miguel Gil, Carles Blanch, Alexander M Walker. (United States)
- 113 Comorbidity Influence in COPD: Attributable Mortality Risks [587]**  
Victor A Kiri, James Oyee. (United Kingdom)
- 114 Global Cardiovascular Risk Screening – A Community Pharmacy Based Study [588]**  
SO Martins, J Cabrita, M Caramona, J Vanmil. (Portugal)
- 115 The Incidence of Microvascular and Macrovascular Complications in Koreans with Type 2 Diabetes: REKORD Study [589]**  
Yooni Kim, Dong-Seop Choi, Byung-Joo Park, Myong-Joo Byun, Yil-Seob Lee, REKORD Study Group. (Korea)
- 116 Do Non Responders Differ from Responders in a Mailed Questionnaire among Users of Inhaled Corticosteroids? [590]**  
Tanja T Menckeberg, Marcel L Bouvy, Madelon Bracke, Martine Koppelaar, Jan A Raaijmakers, Hubert GM Leufkens. (Netherlands)
- 117 Small Area Prevalence of Diabetes and Hypertension Estimated from the Portuguese National Health Survey Using Bayesian Hierarchical Modelling [591]**  
Valeska Andreozzi, Jorge Félix, Pedro Saramago. (Portugal)
- 118 Risk of Cerebrovascular Event among Patients Newly Diagnosed with Atrial Fibrillation [592]**  
Ana Rui Gomez, Saga Johansson, MariAnn Wallander, Luis-Alberto Garcia-Rodriguez. (Spain)
- 119 Incidence and Natural History of Psoriasis Diagnosed in General Practice [593]**  
Consuelo Huerta, Elena Rivero, Miguel Gil, Luis-Alberto Garcia-Rodriguez. (Spain)
- 120 Knowledge, Attitudes, and Preventive Behaviors for Tuberculosis by Thailand Hospital Healthcare Workers [594]**  
Saisunee Baramee, Anongpon Prapanwong, Siriyong Tipsriraj, Made-ta Kam-in, Penkarn Kanjanarat. (Thailand)
- 121 DDD as a Measure of Disease Prevalence: Possible Pitfalls [595]**  
Marc De Falleur, Johan De Haes, André De Swaef. (Belgium)
- 122 Macular Degeneration and Mortality in NHANES III Participants [596]**  
Bao-Anh Nguyen-Khoa, Earl Goehring, Jr., Winifred Werther, Pavel Napalkov, Judith K Jones. (United States)
- 123 Prevalence of Common Diseases in the Rural Areas of the Eastern Cape, South Africa as Observed by Phelophepa [597]**  
Ilse Truter, Hlabishi F Mohlala, Danie JL Venter. (South Africa)
- 124 Prevalence of Obesity in Portugal [598]**  
Carla P Santos, Mário E Macedo, Catarina P Silva. (Portugal)
- 125 Design and Implementation of the Transthyretin Amyloidosis Cardiac Study (TRACS) To Examine the Natural History of Familial Amyloid Cardiomyopathy (FAC) [599]**  
Matthew W Reynolds, Heather Linz, Sheila Crean, Kursten TenHoor, Jeff Packman, Rodney Falk, Fredrick Ruberg. (United States)
- 126 The Use of Nonlinear Functions To Incorporate Clinical Trial Data into Cost-Effectiveness Analysis: Cabergoline vs Bromocriptine in Hyperprolactinaemia [600]**  
Mónica Inês, Jorge Félix, Cátia Acosta. (Portugal)
- 127 The Impact of Rimonabant on Obesity-Related Diseases and Quality of Life: A Cost – Utility Analysis [601]**  
Christian Hampf, Abraham G Hartzema. (United States)
- 128 Impact of Electronic Prescribing on Use of Generic Medications [602]**  
Michael A Fischer, Christine Vogeli, Margaret Stedman, Rainu Kaushal, Timothy Ferris, Joel S Weissman. (United States)
- 129 A Simple Model for Calculating the Incidence of Rare Tumours in Other Countries – An Example Using the Incidence of Glioblastoma Multiforme in the United Kingdom [603]**  
Simon Voss, Vivian Mak, Steve George, Kenneth Hornbuckle. (United Kingdom)
- 130 Factors Associated with Spending on Inappropriate Medicines among Elderly People in Belo Horizonte, Brazil [604]**  
Marina G Lima, Andreia Q Ribeiro, Francisco A Acurcio, Suely Rozenfeld, Carlos H Klein. (Brazil)
- 131 Pharmacoepidemiological Aspects of Reforms of Pharmaceutical Part of Republic Health Financial Service in Montenegro Republic [605]**  
Zdenko Tomić, Ana Sabo, Momir Mikov, Ramo Bralic, Zoran Glomazic, Vujica Lazovic. (Yugoslavia)
- 132 HMG-COA Reductase Inhibitors and Fracture Risk-A Meta-Analysis [606]**  
Sengwee Toh, Sonia Hernández-Díaz. (United States)
- 133 Incident Hematologic Malignancies and Solid Tumors and Their Date of Diagnosis Can Be Identified with High Specificity in Medicare Claims Data [607]**  
Soko Setoguchi, Daniel H Solomon, Robert J Glynn, E Francis Cook, Sebastian Schneeweiss. (United States)
- 134 Prescriber Non-Participation in the CADEUS Study Did Not Induce Patient Selection Bias [608]**  
Fanny Depont, Nicholas Moore, Cecile Droz, Michel Amouretti, Patrick Blin, Annie Fourier, The CADEUS Study Team. (France)
- 135 Measuring Treatment Adherence Using the DDD Concept [609]**  
Frank Meyer, Gerd Glaeske. (Germany)
- 136 Accuracy of Recall of Recent Medication Use [610]**  
Carol Louik, Judith P Kelly, David W Kaufman, Theresa Anderson, Lynn Rosenberg, Allen A Mitchell. (United States)

- 137 **Use of the Electronic Medical Records (EMR) for Safety Surveillance: Biologics as an Example [611]**  
Hilal Maradit Kremers, Serguei V Pakhomov, Cynthia D Crowson, Nilay D Shah, Sherine E Gabriel. (United States)
- 138 **Potential Bias Due to Selection of Controls in Secondary Data Analysis: Nonaspirin Nonsteroidal Anti-Inflammatory Drugs (NNSAIDs) and Hemorrhagic Stroke [612]**  
Nam-Kyong Choi, Seokyoung Hahn, Seung-Mi Lee, Byung-Joo Park, Byung-Woo Yoon. (Korea)
- 139 **Validity of a Modified PUQE Scoring Index To Assess Severity of Nausea and Vomiting of Pregnancy (NVP); Effect of Antiemetic Utilisation [613]**  
Anais Lacasse, Evelyne Rey, Erna Ferreira, Caroline Morin, Anick Berard. (Canada)
- 140 **Hungarian Hospital Antibiotic Consumption. Does It Matter Which Measure? [614]**  
Ria Benko, Maria Matuz, Peter Doro, Reka Viola, Edit Hajdu, Gyongyver Soos. (Hungary)
- 141 **The Development of the Quantitative Instrument for Assessing the Quality of Clinical Trial Reports [615]**  
Peishan Wang, Dengyuan Zhou, Zhenlin Jia, Lijian Li, Jiang Tian. (China)
- 142 **Does Where You Distributed Impact What You Get? The Role of Distribution Method on Response Rates and Positivity Bias in a Patient Safety Questionnaire in Nursing Homes [616]**  
Kate L Lapane, Brian J Quilliam, Carmel M Hughes. (United States)
- 143 **Making a Curriculum Vita Numerical and Graphical for Tenure, Promotion and Career Awards [617]**  
Charlie H Goldsmith. (Canada)
- 144 **Iressa and Interstitial Lung Disease (ILD) in Japan – Lessons from a Large Nested Case-Control Study To Evaluate a Safety Issue [618]**  
Fredrik Nyberg, Shuji Hada, Kenneth J Rothman, The Iressa CCS Collaborator Group. (Sweden)
- 145 **Methotrexate: Patient Knowledge of Key Safety Issues [619]**  
Anthony R Cox, Carol Higham, Michelle L Chandler, R D Situnayake. (United Kingdom)
- 146 **Prevention of Chemotherapy Related Errors – One Step Toward [620]**  
Catarina Oliveira, Filipa Duarte-Ramos, José Cabrita. (Portugal)
- 147 **Concomitant Prescribing Rates of Statins and Cytochrome P450 3A4 Inhibitors and Inducers in Real-World Clinical Practice [621]**  
Michael H Davidson, Sanjay K Gandhi, Eileen E Ming, Xiongkan Ke, Pollack S Pia, Marcelo A Marotti, McKenney M James. (United States)
- 148 **Safety Profile of Rosuvastatin as Used in General Practice in England: A Prescription-Event Monitoring Study [622]**  
Rachna Kasliwal, Lynda Wilton, Saad Shakir. (United Kingdom)
- 149 **Mass Media Reporting of Cancer Drug Risks [623]**  
Jessica M Fishman. (United States)
- 150 **Risk Management in Dyslipidemic Patients in a Portuguese Community Pharmacy [624]**  
Claudia A Pereira, Joaquim Cabrita. (Portugal)
- 151 **Risk-Benefit Assessment of Drug Interventions Using Multicriteria Decision Modeling [625]**  
Rebecca A Noel, James C Felli, Patrizia Cavazzoni. (United States)
- 152 **Determinants of Drug-Information Needs during Consultation Hours [626]**  
Anuschka S Niemeijer, Jan Schuling, Flora M Haaijer-Ruskamp. (Netherlands)
- 153 **The Use of Thalidomide as Unapproved Drug: Time Trend and the Impact of the Clinical Guideline in Japan [627]**  
Hikaru Watanabe, Eri Kawabe, Nobuhiro Ooba, Tsugumichi Sato, Yong Sa Lim, Kiyoshi Kubota. (Japan)
- 154 **Managing Therapeutic Risk in Portuguese Community Pharmacies: A Feasibility Study [628]**  
Mara P Guerreiro, Judith A Cantrill, Ana P Martins. (United Kingdom)
- 155 **Herbal and Dietary Supplement Use in Older American Women [629]**  
C W Shinoff, L Chang, L Lui, F Modugno, D C Bauer. (United States)
- 156 **Adherence with Proton Pump Inhibitors and Non-Selective NSAIDs and Impact on Gastrointestinal Hospitalizations [630]**  
Sjoukje van der Bij, Nancy Breekveldt-Postma, Wim G Goettsch, Connie Chen, Joelle Erkens, Ron MC Herings. (Netherlands)
- 157 **Adherence to Evidence-Based Statin Guidelines Reduces Risk for Acute Myocardial Infarction by 40% [631]**  
Fernie JA Penning-van Beest, Wim G Goettsch, Olaf H Klungel, John JP Kastelein, Ron MC Herings. (Netherlands)
- 158 **The Effect of Nonsteroidal Anti-Inflammatory Drugs on the Therapy of Antihypertensive Drugs [632]**  
Chieko Ishiguro, Toshiharu Fujita, Takeshi Mayama, Takashi Omori, Tosiya Sato. (Japan)
- 159 **Compliance with Bisphosphonate Therapy Reduces Risk of Osteoporotic Fracture by 25-30% in Post-Menopausal Women [633]**  
Fernie JA Penning-van Beest, Christel HA van den Boogaard, Joëlle A Erkens, Astrid MT Engbersen, Ron MC Herings. (Netherlands)
- 160 **Adherence to Clinical Quidelines in Empiric Antibiotics Choice and Its Influence on Outcomes of Community-Acquired Pneumonia in Hospitalized Belarussian Patients [634]**  
Maxim N Mily, Marina M Sachek, Vladimir Y Lugovoy, Gennadiy G Voronov. (Belarus)
- 161 **Post-Marketing Surveillance Study for the Efficacy and Safety of Vardenafil among Patients with Erectile Dysfunction in Primary Care [635]**  
Young-Sik Kim, Chul-Min Kim, Sung Sunwoo. (Korea)
- 162 **Effect of Academic Detailing on Antibiotic Prescribing among General Practitioners (GPs) [636]**  
Corina Naughton, Kathleen Bennett, John Feely. (Ireland)
- 163 **Infant Mortality Rates Reduction with Haemophilus Influenzae Vaccination in Colombia [637]**  
Fernando Guerrero, Diego A Arboleda. (Colombia)
- 164 **Self-Reported Compliance with Antiresorptive Treatment [638]**  
Magda Vytrisalova, Sarka Blazkova, Jiri Vlcek. (Czech Republic)

- 165 Anticonvulsants' Use in Adolescents [639]  
 Rimma G Gamirova, Svetlana N Sivkova, Fanya M Zaikova, Lilia E Ziganshina. (Russian Federation)
- 166 Effects on Asthma Mortality Rates in Italy after the Introduction of Long Acting b-2 Agonists (LABAs) [640]  
 Francesco Bamfi, Matteo Dionisi, Gabriele Lazzeri. (Italy)
- 167 Utilization of Central Nervous System Stimulants (CNSS) in Children and Adolescents with Attention Deficit Hyperactivity Disorder (ADHD): A Study of Florida Medicaid Beneficiaries 1994-2004 [641]  
 Almut G Winterstein, Tobias Gerhard. (United States)
- 168 Prescription of Fixed Combinations of Inhaled Glucocorticosteroid and Long-Acting b2-Agonists for Childhood Asthma in Denmark: Are Guidelines Followed? [642]  
 Hans K Madsen, Claudia Rannerries, Hans Bisgaard. (Denmark)
- 169 Alternative Strategies for Diagnosis and Treatment of Pediatric Acute Otitis Media [643]  
 Sharon B Meropol, Henry A Glick, David A Asch. (United States)
- 170 Demographic Discrepancies in Diagnosis of Attention Deficit Hyperactivity Disorder (ADHD) and Initiation of Pharmacological Treatment in Children and Adolescents: A Study of Florida Medicaid Beneficiaries 1994-2004 [644]  
 Almut G Winterstein, Tobias Gerhard. (United States)
- 171 Trends in Off-Label and Unlicensed Prescribing of Psychotropic Drugs to Children in Primary Care (2001-2004) [645]  
 Anita C Volkers, Liset van Dijk. (Netherlands)
- 172 A Double-Blind, Placebo-Controlled Study of Olanzapine in Adolescents with Schizophrenia [646]  
 Ludmila Kryzhanovskaya, Charles Schulz, Christopher J McDougale, Jean A Frazier, Ralf W Dittmann, Carol Robertson-Plouch, Theresa Bauer, Wen Xu, Wei V Wang, Janice Carlson, Mauricio Tohen. (United States)
- 173 Primary Insomnia in Pediatrics [647]  
 Laura E Bursleson. (United States)
- 174 Olanzapine in the Treatment of Acute Mania in Adolescents with Bipolar I Disorder: a 3-Week Randomized Double-Blind Placebo-Controlled Study [648]  
 Mauricio Tohen, Ludmila Kryzhanovskaya, Gabrielle Carlson, Melissa DelBello, Janet Wozniak, Robert Kowatch, Karen Wagner, Robert Findling, Daniel Lin, Carol Robertson-Plouch, Wen Xu, Ralf Dittmann, Joe Biederman. (United States)

◀ END SESSION C



**Procter & Gamble  
Pharmaceuticals**

We are passionately committed to building mutually beneficial partnerships with academia, biotechnology and other pharmaceutical companies.

You and P&G... Think of the possibilities.

Touching lives, improving life. **P&G™**